Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 49
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior

  • Plaza-Zabala, Ainhoa, 1982-
  • Flores de los Heros, África, 1985-
  • Martín García, Elena, 1975-
  • Saravia Santos, Rocio, 1988-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
Hypocretin/orexin signaling is critically involved in relapse to drug-seeking behaviors. In this study, we investigated the involvement of the hypocretin system in the reinstatement of nicotine-seeking behavior induced by nicotine-associated cues. Pretreatment with the hypocretin receptor-1 antagonist SB334867, but not with the hypocretin receptor-2 antagonist TCSOX229, attenuated cue-induced reinstatement of nicotine-seeking, which was associated with an activation of hypocretin neurons of the lateral and perifornical hypothalamic areas. In addition, relapse to nicotine-seeking increased the phosphorylation levels of GluR2-Ser880, NR1-Ser890, and p38 MAPK in the nucleus accumbens (NAc), but not in the prefrontal cortex. Notably, phosphorylation levels of NR1-Ser890 and p38 MAPK, but not GluR2-Ser880, were dependent on hypocretin receptor-1 activation. The intra-accumbens infusion of the protein kinase C (PKC) inhibitor NPC-15437 reduced nicotine-seeking behavior elicited by drug-paired cues consistent with the PKC-dependent phosphorylations of GluR2-Ser880 and NR1-Ser890. SB334867 failed to modify cue-induced reinstatement of food-seeking, which did not produce any biochemical changes in the NAc. These data identify hypocretin receptor-1 and PKC signaling as potential targets for the treatment of relapse to nicotine-seeking induced by nicotine-associated cues., This work was supported by the Instituto de Salud Carlos III grants, #PI07/0559, #PI10/00316 and #RD06/001/001 (RTA-RETICS), by the Spanish Ministry of Science and Technology, Consolider-C #SAF2007-64062 and #SAF2011-29864, the Catalan Government (SGR2009-00731), and by the Catalan Institution for Research and Advanced Studies (ICREA Academia program). Ainhoa Plaza-Zabala and África Flores are recipients of a predoctoral fellowship from the Spanish Ministry of Education
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Differential regulation of mGlu5 R and ΜOPr by priming- and cue-induced reinstatement of cocaine-seeking behaviour in mice

  • Georgiou, Polymnia
  • Zanos, Panos
  • Ehteramyan, Mazdak
  • Hourani, Susanna
  • Kitchen, Ian
  • Maldonado, Rafael, 1961-
  • Bailey, Alexis
The key problem for the treatment of drug addiction is relapse to drug use after abstinence that can be triggered by drug-associated cues, re-exposure to the drug itself and stress. Understanding the neurobiological mechanisms underlying relapse is essential in order to develop effective pharmacotherapies for its prevention. Given the evidence implicating the metabotropic glutamate receptor 5 (mGlu5 R), μ-opioid receptor (MOPr), κ-opioid receptor (ΚOPr) and oxytocin receptor (OTR) systems in cocaine addiction and relapse, our aim was to assess the modulation of these receptors using a mouse model of cue- and priming-induced reinstatement of cocaine seeking. Male mice were trained to self-administer cocaine (1 mg/kg/infusion, i.v.) and were randomized into different groups: (1) cocaine self-administration; (2) cocaine extinction; (3) cocaine-primed (10 mg/kg i.p.); or (4) cue-induced reinstatement of cocaine seeking. Mice undergoing the same protocols but receiving saline instead of cocaine were used as controls. Quantitative autoradiography of mGlu5 R, MOPr, KOPr and OTR showed a persistent cocaine-induced upregulation of the mGlu5 R and OTR in the lateral septum and central amygdala, respectively. Moreover, a downregulation of mGlu5 R and MOPr was observed in the basolateral amygdala and striatum, respectively. Further, we showed that priming- but not cue-induced reinstatement upregulates mGlu5 R and MOPr binding in the nucleus accumbens core and basolateral amygdala, respectively, while cue- but not priming-induced reinstatement downregulates MOPr binding in caudate putamen and nucleus accumbens core. This is the first study to provide direct evidence of reinstatement-induced receptor alterations that are likely to contribute to the neurobiological mechanisms underpinning relapse to cocaine seeking., This work was supported by Spanish‘ Ministerio de Ciencia e Innovación’ (SAF 2011–29864) and Lilia and Charalambos Georgiou
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model

  • Busquets Garcia, Arnau, 1985-
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Fragile X syndrome is the most common monogenetic form of intellectual disability and is a leading cause of autism. This syndrome is produced by the reduced transcription of the fragile X mental retardation (FMR1) gene, and it is characterized by a range of symptoms heterogeneously expressed in patients such as cognitive impairment, seizure susceptibility, altered pain sensitivity and anxiety. The recent advances in the understanding of the pathophysiological mechanisms involved have opened novel potential therapeutic approaches identified in preclinical rodent models as a necessary preliminary step for the subsequent evaluation in patients. Among those possible therapeutic approaches, the modulation of the metabotropic glutamate receptor signaling or the GABA receptor signaling have focused most of the attention. New findings in the animal models open other possible therapeutic approaches such as the mammalian target of rapamycin signaling pathway or the endocannabinoid system. This review summarizes the emerging data recently obtained in preclinical models of fragile X syndrome supporting these new therapeutic perspectives., AB-G was recipient of a predoctoral fellowship (Ministerio de Educación y Cultura) and supported by “Investments for the future” Programme IdEx Bordeaux (ANR-10-IDEX-03-02, French National Research Agency). Related research on the subject was supported by grants from FRAXA Research Foundation (A.O.), Jérôme Lejeune Foundation (A.O.), Ministerio de Ciencia e Innovación (#BFU2012-33500 to A.O., #SAF2011-29864 to R.M.); Instituto de Salud Carlos III (RD06/0001/0001 to R.M.); PLAN E (Plan Español para el Estímulo de la Economía y el Empleo); Generalitat de Catalunya (SGR-2009-00731 to R.M.); ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to R.M.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain

  • La Porta, Carmen, 1985-
  • Bura, S. Andreea, 1978-
  • Llorente Onaindia, Jone
  • Pastor, Antonio
  • Navarrete, Francisco
  • García-Gutiérrez, María S.
  • Torre Fornell, Rafael de la
  • Manzanares, Jorge
  • Monfort, Jordi
  • Maldonado, Rafael, 1961-
In this study, we investigated the role of the endocannabinoid system (ECS) in the emotional and cognitive alterations associated with osteoarthritis pain. The monosodium iodoacetate model was used to evaluate the affective and cognitive manifestations of osteoarthritis pain in type 1 (CB1R) and type 2 (CB2R) cannabinoid receptor knockout and wild-type mice and the ability of CB1R (ACEA) and CB2R (JWH133) selective agonists to improve these manifestations during a 3-week time period. The levels of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were measured in plasma and brain areas involved in the control of these manifestations. Patients with knee osteoarthritis and healthy controls were recruited to evaluate pain, affective, and cognitive symptoms, as well as plasma endocannabinoid levels and cannabinoid receptor gene expression in peripheral blood lymphocytes. The affective manifestations of osteoarthritis were enhanced in CB1R knockout mice and absent in CB2R knockouts. Interestingly, both ACEA and JWH133 ameliorated the nociceptive and affective alterations, whereas ACEA also improved the associated memory impairment. An increase of 2-AG levels in prefrontal cortex and plasma was observed in this mouse model of osteoarthritis. In agreement, an increase of 2-AG plasmatic levels and an upregulation of CB1R and CB2R gene expression in peripheral blood lymphocytes were observed in patients with osteoarthritis compared with healthy subjects. Changes found in these biomarkers of the ECS correlated with pain, affective, and cognitive symptoms in these patients. The ECS plays a crucial role in osteoarthritis and represents an interesting pharmacological target and biomarker of this disease., This work was supported by European Commission-FP7 (#HEALTH-F2-2013-602891), RETICS-Instituto de Salud Carlos III (#RD12/0028/0023), MICINN-Ministerio de Ciencia e Innovación (#SAF2011-29864), AGAUR-Generalitat de Catalunya (#2009SGR00731), #2014-SGR-680 and #2014-SGR-1547). ISCIII-FIS-CAIBER (CAI08/01/0024), CIBEROBN (CB06/03/0028). CIBEROBN is an initiative of Instituto de Salud Carlos III, Madrid, Spain. FEDER co-funding is also acknowledged.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors.

  • Viñals Álvarez, Xavier, 1985-
  • Moreno, Estefanía
  • Lanfumey, Laurence
  • Cordomí, Arnau
  • Pastor, Antonio
  • Torre Fornell, Rafael de la
  • Gasperini, Paola
  • Navarro, Gemma
  • Howell, Lesley A.
  • Pardo, Leonardo
  • Lluís, Carmen
  • Canela, Enric I.
  • McCormick, Peter J.
  • Maldonado, Rafael, 1961-
  • Robledo, Patricia, 1958-
Activation of cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) produces a variety of negative effects with major consequences in cannabis users that constitute important drawbacks for the use of cannabinoids as therapeutic agents. For this reason, there is a tremendous medical interest in harnessing the beneficial effects of THC. Behavioral studies carried out in mice lacking 5-HT2A receptors (5-HT2AR) revealed a remarkable 5-HT2AR-dependent dissociation in the beneficial antinociceptive effects of THC and its detrimental amnesic properties. We found that specific effects of THC such as memory deficits, anxiolytic-like effects, and social interaction are under the control of 5-HT2AR, but its acute hypolocomotor, hypothermic, anxiogenic, and antinociceptive effects are not. In biochemical studies, we show that CB1R and 5-HT2AR form heteromers that are expressed and functionally active in specific brain regions involved in memory impairment. Remarkably, our functional data shows that costimulation of both receptors by agonists reduces cell signaling, antagonist binding to one receptor blocks signaling of the interacting receptor, and heteromer formation leads to a switch in G-protein coupling for 5-HT2AR from Gq to Gi proteins. Synthetic peptides with the sequence of transmembrane helices 5 and 6 of CB1R, fused to a cell-penetrating peptide, were able to disrupt receptor heteromerization in vivo, leading to a selective abrogation of memory impairments caused by exposure to THC. These data reveal a novel molecular mechanism for the functional interaction between CB1R and 5-HT2AR mediating cognitive impairment. CB1R-5-HT2AR heteromers are thus good targets to dissociate the cognitive deficits induced by THC from its beneficial antinociceptive properties., This study was supported by grants from the Spanish ‘Ministerio de Ciencia e Innovación’ (SAF2011-29864) to RM, SAF2010-18472) to PJM and (SAF2011-23813) to EC. ‘Ministerio de Economía y Competitividad’ (SAF2014-59648-P) to RM. The Spanish ‘Instituto de Salud Carlos III’ (P1070709 and PI14/00210) to PR and (RD06/001/ 001) to RM, the Catalan government (SGR2009- 00131) to RM. PJM was supported by a Ramon y Cajal Fellow and internal funds from UEA, and PJM and LP participate in the European COST Action CM 1207 (GLISTEN). FEDER funds partial support is also acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A novel anxiogenic role for the delta opioid receptor expressed in GABAergic forebrain neurons

  • Chung, Paul Chu Sin
  • Keyworth, Helen L.
  • Martín García, Elena, 1975-
  • Charbogne, Pauline
  • Darcq, Emmanuel
  • Bailey, Alexis
  • Filliol, Dominique
  • Matifas, Audrey
  • Scherrer, Grégory
  • Ouagazzal, Abdel-Mouttalib
  • Gaveriaux-Ruff, Claire
  • Befort, Katia
  • Maldonado, Rafael, 1961-
  • Kitchen, Ian
  • Kieffer, Brigitte L.
BACKGROUND: The delta opioid receptor (DOR) is broadly expressed throughout the nervous system; it regulates chronic pain, emotional responses, motivation, and memory. Neural circuits underlying DOR activities have been poorly explored by genetic approaches. We used conditional mouse mutagenesis to elucidate receptor function in GABAergic neurons of the forebrain. METHODS: We characterized DOR distribution in the brain of Dlx5/6-CreXOprd1(fl/fl) (Dlx-DOR) mice and tested main central DOR functions through behavioral testing. RESULTS: The DOR proteins were strongly deleted in olfactory bulb and striatum and remained intact in cortex and basolateral amygdala. Olfactory perception, circadian activity, and despair-like behaviors were unchanged. In contrast, locomotor stimulant effects of SNC80 (DOR agonist) and SKF81297 (D1 agonist) were abolished and increased, respectively. The Dlx-DOR mice showed lower levels of anxiety in the elevated plus maze, opposing the known high anxiety in constitutive DOR knockout animals. Also, Dlx-DOR mice reached the food more rapidly in a novelty suppressed feeding task, despite their lower motivation for food reward observed in an operant paradigm. Finally, c-fos protein staining after novelty suppressed feeding was strongly reduced in amygdala, concordant with the low anxiety phenotype of Dlx-DOR mice. CONCLUSIONS: We demonstrate that DORs expressed in the forebrain mediate the described locomotor effect of SNC80 and inhibit D1-stimulated hyperactivity. Our data also reveal an unanticipated anxiogenic role for this particular DOR subpopulation, with a potential novel adaptive role. In emotional responses, DORs exert dual anxiolytic and anxiogenic roles, both of which may have implications in the area of anxiety disorders., This work was supported by the Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, and Université de Strasbourg; the Fondation pour la Recherche Médicale (Grant No. FRM FDT20120925269), the U.S. National Institutes of Health (National Institute of Drug Addiction, Grant No. 05010, and National Institute on Alcohol Abuse and Alcoholism, Grant No. 16658); the Spanish Instituto de Salud Carlos III (Red de Trastornos Adictivos, Grant No. RD06/001/001), the Spanish Ministerio de Ciencia e Innovación (No. Ministerio de Ciencia e Innovación [Grant No. SAF2011-29864]), the Catalan Government (Grant No. SGR2009-00131), and Institucio Catalana de Recerca i Estudis Avançats Academia-2008; and NeuroPain (Framework programme 7, European Union)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward

  • Flores de los Heros, África, 1985-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
BACKGROUND: Cannabis is the most widely used illicit drug in the world. Although there is a high prevalence of users who seek treatment for cannabis dependence, no accepted pharmacologic treatment is available to facilitate and maintain abstinence. The hypocretin/orexin system plays a critical role in drug addiction, but the potential participation of this system in the addictive properties of cannabinoids is unknown. METHODS: We investigated the effects of hypocretins in the intravenous self-administration of the synthetic cannabinoid agonist WIN55,212-2 using hypocretin receptor-1 (Hcrtr-1) and hypocretin receptor-2 antagonists and Hcrtr-1 knockout mice. Additional groups of mice were trained to obtain water to rule out operant responding impairments. Activation of hypocretin neurons was analyzed by using double-label immunofluorescence of FosB/ΔFosB with hypocretin-1. Microdialysis studies were performed to evaluate dopamine extracellular levels in the nucleus accumbens after acute Δ(9)-tetrahydrocannabinol administration.RESULTS: Systemic administration of the Hcrtr-1 antagonist SB334867 reduced intravenous self-administration of WIN55,212-2, as well as the maximum effort to obtain a WIN55,212-2 infusion, as revealed under a progressive ratio schedule. This role of Hcrtr-1 in the reinforcing and motivational properties of WIN55,212-2 was confirmed in Hcrtr-1 knockout mice. Contingent, but not noncontingent, WIN55,212-2 self-administration increased the percentage of hypocretin cells expressing FosB/ΔFosB in the lateral hypothalamus. The enhancement in dopamine extracellular levels in the nucleus accumbens induced by Δ(9)-tetrahydrocannabinol was blocked in mice lacking the Hcrtr-1. CONCLUSIONS: /nThese findings demonstrate that Hcrtr-1 modulates the reinforcing properties of cannabinoids, which could have a clear therapeutic interest., This work was supported by the Instituto de Salud Carlos III grants, #PI07/0559, #PI10/00316 and #RD06/001/001 (RTA-RETICS), by the Spanish Ministry of Science and Technology, Consolider-C #SAF2007-64062 and #SAF2011-29864, the Catalan Government (SGR2009-00731), and by the Catalan Institution for Research and Advanced Studies (ICREA Academia program). África Flores is recipient of a predoctoral fellowship from the Spanish Ministry of Education
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Looking for prosocial genes: ITRAQ analysis of proteins involved in MDMA-induced sociability in mice

  • Kuteykin-Teplyakov, Konstantin
  • Maldonado, Rafael, 1961-
Social behavior plays a fundamental role in life of many animal species, allowing the interaction between individuals and sharing of experiences, needs, and goals across them. In humans, some neuropsychiatric diseases, including anxiety, posttraumatic stress disorder and autism spectrum disorders, are often characterized by impaired sociability. Here we report that N-Methyl-3,4-methylenedioxyamphetamine (MDMA, "Ecstasy") at low dose (3mg/kg) has differential effects on mouse social behavior. In some animals, MDMA promotes sociability without hyperlocomotion, whereas in other mice it elevates locomotor activity without affecting sociability. Both WAY-100635, a selective antagonist of 5-HT1A receptor, and L-368899, a selective oxytocin receptor antagonist, abolish prosocial effects of MDMA. Differential quantitative analysis of brain proteome by isobaric tag for relative and absolute quantification technology (iTRAQ) revealed 21 specific proteins that were highly correlated with sociability, and allowed to distinguish between entactogenic prosocial and hyperlocomotor effects of MDMA on proteome level. Our data suggest particular relevance of neurotransmission mediated by GABA B receptor, as well as proteins involved in energy maintenance for MDMA-induced sociability. Functional association network for differentially expressed proteins in cerebral cortex, hippocampus and amygdala were identified. These results provide new information for understanding the neurobiological substrate of sociability and may help to discover new therapeutic approaches to modulate social behavior in patients suffering from social fear and low sociability., This work was supported by the Spanish “Ministerio de Ciencia e Innovación” (SAF2011-29864); Spanish “Instituto de Salud Carlos III” (RETICS – Red de Trastornos Adictivos – Redes Temáticas de Investigación Cooperativa en Salud: #RD06/0001/0001, #RD06/0001/1004); Spanish “Plan Nacional sobre Drogas” (PNSD #2009/026); the Catalan Government (SGR2009-00131); and the ICREA Foundation (ICREA Academia-2008). KK-T was supported by a Marie Curie Intra-European Fellowship from the European Commission (MC-2010-274950)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The hypocretin/orexin system mediates the extinction of fear memories

  • Flores de los Heros, África, 1985-
  • Valls Comamala, Victòria, 1987-
  • Costa, Giulia
  • Saravia Santos, Rocio, 1988-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
Anxiety disorders are often associated with an inability to extinguish learned fear responses. The hypocretin/orexin system is involved in the regulation of emotional states and could also participate in the consolidation and extinction of aversive memories. Using hypocretin receptor-1 and hypocretin receptor-2 antagonists, hypocretin-1 and hypocretin-2 peptides, and hypocretin receptor-1 knockout mice, we investigated the role of the hypocretin system in cue- and context-dependent fear conditioning and extinction. Hypocretins were crucial for the consolidation of fear conditioning, and this effect was mainly observed in memories with a high emotional component. Notably, after the acquisition of fear memory, hypocretin receptor-1 blockade facilitated fear extinction, whereas hypocretin-1 administration impaired this extinction process. The extinction-facilitating effects of the hypocretin receptor-1 antagonist SB334867 were associated with increased expression of cFos in the basolateral amygdala and the infralimbic cortex. Intra-amygdala, but neither intra-infralimbic prefrontal cortex nor intra-dorsohippocampal infusion of SB334867 enhanced fear extinction. These results reveal a key role for hypocretins in the extinction of aversive memories and suggest that hypocretin receptor-1 blockade could represent a novel therapeutic target for the treatment of diseases associated with inappropriate retention of fear, such as post-traumatic stress disorder and phobias., This work was supported by the Instituto de Salud Carlos III grants, #PI13/00042 and #RD12/0028/0023 (RTA-RETICS), by the Spanish Ministry of Science #SAF2011-29864, the/nCatalan Government (SGR2009-00731), and by the Catalan Institution for Research and Advanced Studies (ICREA Academia program). África Flores is a recipient of a predoctoral fellowship from the Spanish Ministry of Education.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Endocannabinoid system and drug addiction: new insights from mutant mice approaches

  • Maldonado, Rafael, 1961-
  • Robledo, Patricia, 1958-
  • Berrendero Díaz, Fernando, 1971-
The involvement of the endocannabinoid system in drug addiction was initially studied by the use of compounds with different affinities for each cannabinoid receptor or for the proteins involved in endocannabinoids inactivation. The generation of genetically modified mice with selective mutations in these endocannabinoid system components has now provided important advances in establishing their specific contribution to drug addiction. These genetic tools have identified the particular interest of CB1 cannabinoid receptor and endogenous anandamide as potential targets for drug addiction treatment. Novel genetic tools will allow determining if the modulation of CB2 cannabinoid receptor activity and 2-arachidonoylglycerol tone can also have an important therapeutic relevance for drug addiction., This work was supported by the Spanish “Ministerio de Ciencia e Innovación” (#SAF2007-64062 and SAF2011-29864), “Instituto de Salud Carlos III” (RETICS- Red de Trastornos Adictivos-Redes Temáticas de Investigación Cooperativa en Salud: #RD06/0001/0001, #RD06/0001/1004), grants #10/00316 and #10/01708, Plan Nacional sobre Drogas (PNSD #2009/026), the Catalan Government (SGR2009-00131) and the ICREA Foundation (ICREA Academia-2008)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Orexins and fear: implications for the treatment of anxiety disorders

  • Flores de los Heros, África, 1985-
  • Saravia Santos, Rocio, 1988-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
An understanding of the neurobiological mechanisms involved in the regulation of fear is essential for the development of new treatments for anxiety disorders, such as phobias, panic, and post-traumatic stress disorders (PTSD). Orexins, also known as hypocretins, are neuropeptides located exclusively in hypothalamic neurons that have extensive projections throughout the central nervous system. Although this system was initially believed to be primarily involved in the regulation of feeding behavior, recent studies have shown that orexins also modulate neural circuits implicated in the expression and extinction of fear memories. Here, we discuss recent findings involving orexins in anxiety disorders and current clinical trials using orexin ligands that could be applied to identify new therapies for diseases characterized by pathological fear., This work was supported by the Instituto de Salud Carlos III grants, #PI13/00042 and #RD12/0028/0023 (RTA-RETICS), by the Spanish Ministry of Science #SAF2011-29864 and #SAF2014-59648-P, National Plan on Drugs #2014I019, and the Catalan Government (SGR2014-1547).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Epigenetic and proteomic expression changes promoted by eating addictive-like behavior

  • Mancino, Samantha, 1987-
  • Burokas, Aurelijus, 1982-
  • Gutiérrez Cuesta, Javier
  • Gutiérrez Martos, Miriam, 1989-
  • Martín García, Elena, 1975-
  • Pucci, Mariangela
  • Falconi, Anastasia
  • D'Addario, Claudio
  • Maccarrone, Mauro
  • Maldonado, Rafael, 1961-
An increasing perspective conceptualizes obesity and overeating as disorders related to addictive-like processes that could share common neurobiological mechanisms. In the present study, we aimed at validating an animal model of eating addictive-like behavior in mice, based on the DSM-5 substance use disorder criteria, using operant conditioning maintained by highly palatable chocolate-flavored pellets. For this purpose, we evaluated persistence of food-seeking during a period of non-availability of food, motivation for food, and perseverance of responding when the reward was associated with a punishment. This model has allowed identifying extreme subpopulations of mice related to addictive-like behavior. We investigated in these subpopulations the epigenetic and proteomic changes. A significant decrease in DNA methylation of CNR1 gene promoter was revealed in the prefrontal cortex of addict-like mice, which was associated with an upregulation of CB1 protein expression in the same brain area. The pharmacological blockade (rimonabant 3 mg/kg; i.p.) of CB1 receptor during the late training period reduced the percentage of mice that accomplished addiction criteria, which is in agreement with the reduced performance of CB1 knockout mice in this operant training. Proteomic studies have identified proteins differentially expressed in mice vulnerable or not to addictive-like behavior in the hippocampus, striatum, and prefrontal cortex. These changes included proteins involved in impulsivity-like behavior, synaptic plasticity, and cannabinoid signaling modulation, such as alpha-synuclein, phosphatase 1-alpha, doublecortin-like kinase 2, and diacylglycerol kinase zeta, and were validated by immunoblotting. This model provides an excellent tool to investigate the neurobiological substrate underlying the vulnerability to develop eating addictive-like behavior., This work was supported by the DG Research of the European Commission FP7 (No. HEALTH-F2 2013-602891), the Spanish ‘RETICS-Instituto de Salud Carlos III’ (No. RD12/0028/0023), the Spanish ‘Ministerio de Ciencia e Innovación’ (No. SAF2011-29864), and the Catalan Government ‘AGAUR-Generalitat de Catalunya’ (Nos. 2009SGR00731 and 2014-SGR-1547). The FEDER funds support is also acknowledged. SM and AB were supported by FI predoctoral fellowships of the Catalan Government, and JG-C was supported by a ‘Juan de la Cierva’ postdoctoral fellowship from the Spanish ‘Ministerio de Ciencia e Innovación’. Also support by the Italian Ministry of University and Research under grants FIRB-RBFR12DELS to CDA and PRIN2010-11 to MM is gratefully acknowledged. The authors declare no conflict of interest.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Baclofen and 2-hydroxysaclofen modify acute hypolocomotive and antinociceptive effects of nicotine

  • Varani, Andrés P.
  • Aso Pérez, Ester
  • Maldonado, Rafael, 1961-
  • Balerio, Graciela N.
The aim of the present study was to evaluate the possible involvement of GABAB receptors in nicotine-induced hypolocomotion and antinociceptive effects in mice. Animals were exposed to nicotine only once. Acute nicotine hydrogen tartrate salt (3mg/kg; subcutaneous, s.c.) administration induced hypolocomotion and antinociceptive responses in the tail-immersion and the hot-plate tests. The effects of pretreatment with either the GABAB receptor agonist baclofen (1, 2 and 3mg/kg; intraperitoneal, i.p.) or GABAB receptor antagonist 2-hydroxysaclofen (0.25, 0.5 and 1mg/kg; i.p.) were evaluated on these behavioral nicotine responses. The GABAB receptor agonist, baclofen (3mg/kg, i.p.) abolished nicotine-induced antinociceptive effects in the tail-immersion and the hot-plate tests, but did not modify nicotine-induced hypolocomotion. In addition, the GABAB receptor antagonist, 2-hydroxysaclofen (1mg/kg, i.p.) increased nicotine-induced antinociceptive effects in the tail-immersion and the hot-plate tests, and abolished nicotine-induced hypolocomotion. The present results shed light that the GABAB receptor has an important role in mediating specific acute nicotine responses such as hypolocomotion and antinociception in mice., This work has been supported by grants from University of Buenos Aires (UBACyT B016 and UBACyT 2013–2016 No. 20020120100244), CONICET (PIP 11420090100303), Spanish “Ministerio de Ciencia e Innovación” (#SAF2011-29864), “Instituto de Salud Carlos III” (RETICS: #RD06/0001/0001, #RD06/0001/1004), Plan Nacional sobre Drogas (PNSD #2009/026), the Catalan Government (SGR2009-00131) and the ICREA Foundation (ICREA Academia-2008)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Influence of δ-opioid receptors in the behavioral effects of nicotine

  • Berrendero Díaz, Fernando, 1971-
  • Plaza-Zabala, Ainhoa, 1982-
  • Galeote González, Lola
  • Flores de los Heros, África, 1985-
  • Bura, S. Andreea, 1978-
  • Kieffer, Brigitte L.
  • Maldonado, Rafael, 1961-
Multiple studies in animal models and humans suggest that the endogenous opioid system is an important neurobiological substrate for nicotine addictive properties. In this study, we evaluated the participation of δ-opioid receptors in different behavioral responses of nicotine by using δ-opioid receptor knockout mice. Acute nicotine administration induced hypolocomotion and antinociception in wild-type mice, which were similar in knockout animals. The development of tolerance to nicotine-induced antinociception was also similar in both genotypes. In agreement, the expression and functional activity of δ-opioid receptors were not modified in the different layers of the spinal cord and brain areas evaluated after chronic nicotine treatment. The somatic manifestation of the nicotine withdrawal syndrome precipitated by mecamylamine was also similar in wild-type and δ-opioid receptor knockout mice. In contrast, nicotine induced a conditioned place preference in wild-type animals that was abolished in knockout mice. Moreover, a lower percentage of acquisition of intravenous nicotine self-administration was observed in mice lacking δ-opioid receptors as well as in wild-type mice treated with the selective δ-opioid receptor antagonist naltrindole. Accordingly, in-vivo microdialysis studies revealed that the enhancement in dopamine extracellular levels induced by nicotine in the nucleus accumbens was reduced in mutant mice. In summary, the present results show that δ-opioid receptors are involved in the modulation of nicotine rewarding effects. However, this opioid receptor does not participate either in several acute effects of nicotine or in the development of tolerance and physical dependence induced by chronic nicotine administration., This work was supported by the Spanish “Ministerio de Ciencia e Innovación”/n(#SAF2007-64062 and #SAF-2011-29864), the “Instituto de Salud Carlos III” grants/n#PI07/0559, #PI10/00316 and #RD06/001/001, the “Plan Nacional Sobre Drogas”/n(#2009/026), the Catalan Government (SGR2009-00131), and the ICREA Foundation/n(ICREA Academia Award-2008) to R.M. Partial support of FEDER funds is also acknowledged.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations

  • Varani, Andrés P.
  • Aso Pérez, Ester
  • Machado Moutinho, Lirane
  • Maldonado, Rafael, 1961-
  • Balerio, Graciela N.
RATIONALE: Nicotine is a major active ingredient in tobacco and plays a major role in tobacco addiction. In rodents, repeated nicotine administration produces behavioral responses related to its addictive properties, such as reinforcing effects and physical dependence. OBJECTIVES: The aim of the present study was to evaluate the possible role of GABAB receptor in responses induced by repeated nicotine administration in Swiss Webster mice. RESULTS: Nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.) administration induced rewarding properties in the conditioning place preference test. The GABAB receptor agonist, baclofen (3 mg/kg, i.p.) abolished the rewarding properties induced by nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.). In addition, naloxone-precipitated nicotine withdrawal induced somatic manifestations, anxiety-like effects in the elevated plus maze test and dysphoric manifestations in the conditioned place aversion paradigm. Baclofen (2 and 3 mg/kg, i.p.) prevented the somatic manifestations and the anxiety-like effects associated with naloxone-precipitated nicotine withdrawal but not the dysphoric manifestations. CONCLUSIONS: These results showed that nicotine rewarding properties and negative aspects of nicotine withdrawal, such as anxiety-like effects and somatic manifestations, can be modulated by the GABAB receptor activity. This study now reveals a novel possible application of baclofen to develop new therapeutic strategies to achieve smoking cessation., This work has been supported by grants from University of Buenos Aires (UBACyT B016 and UBACyT 2013-2016 Nº 20020120100244), CONICET (PIP 11420090100303), Spanish “Ministerio de Ciencia e Innovación” (#SAF2011-29864), “Instituto de Salud Carlos III” (RETICS: #RD06/0001/0001, #RD06/0001/1004), Plan Nacional sobre Drogas (PNSD#2009/026), the CatalanGovernment/n(SGR2009-00131), and the ICREA Foundation (ICREA Academia-2008). Andrés P. Varani is a doctoral fellow of the University of Buenos Aires (677/10).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9)-tetrahydrocannabinol

  • Flores de los Heros, África, 1985-
  • Julià Hernández, Marina
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
BACKGROUND AND PURPOSE: Anatomical, biochemical and pharmacological evidence suggest the existence of a crosstalk between the orexinergic and endocannabinoid systems. While the orexin receptor 1 (OX1 receptor) modulates the reinforcing properties of cannabinoids, the participation of orexins in the acute pharmacological effects of Δ(9) -tetrahydrocannabinol (THC) remains unexplored. EXPERIMENTAL APPROACH: We assessed the possible role of orexins in THC-induced hypolocomotion, hypothermia, antinociception, anxiolytic- and anxiogenic-like effects and memory impairment. Selective OX1 and OX2 receptor antagonists and OX1 knockout (KO) mice as well as prepro-orexin (PPO) KO mice were used as pharmacological and genetic approaches. CB1 receptor levels in control and PPO KO mice were evaluated by immunoblot analysis. The expression of c-Fos after THC treatment was analysed in several brain areas in wild-type mice and in mice lacking the PPO gene. KEY RESULTS: The hypothermia, supraspinal antinociception and anxiolytic-like effects induced by THC were modulated by orexins through OX2 receptor signalling. OX1 receptors did not seem to be involved in these THC responses. No differences in CB1 receptor levels were found between wild-type and PPO KO mice. THC-induced increase in c-Fos expression was reduced in the central amygdala, medial preoptic area and lateral septum in these mutant mice. CONCLUSIONS AND IMPLICATIONS: Our results provide new findings to further clarify the interaction between orexins and cannabinoids. OX1 and OX2 receptors are differently implicated in the pharmacological effects of cannabinoids., This work was supported by the Instituto de Salud Carlos III grants [#PI13/00042 and #RD12/0028/0023 (RTA-RETICS)], by the Spanish Ministry of Science (#SAF2011-29864 and #SAF2014-59648-P), National Plan on Drugs (#2014I019) and the Catalan Government (SGR2014-1547)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Role of DOR in neuronal plasticity changes promoted by food-seeking behaviour

  • Mancino, Samantha, 1987-
  • Mendonça Netto, Sueli
  • Martín García, Elena, 1975-
  • Maldonado, Rafael, 1961-
Several lines of evidence support that food overconsumption may be related to the role of the endogenous opioid system in the control of food palatability. The opioid system, and particularly the delta opioid receptor (DOR), plays a crucial role in the regulation of food rewarding properties. In our study, we used operant conditioning maintained by chocolate-flavoured pellets to investigate the role of DOR in the motivation for palatable food and the structural plasticity changes promoted by this behaviour. For this purpose, we evaluated the specific role of this receptor in the behavioural and neuroplastic changes induced by palatable food in the prefrontal cortex (PFC), hippocampus (HCP) and nucleus accumbens (NAc) in constitutive knockout (KO) mice deficient in DOR. Mutant mice and their wild-type littermates were trained to obtain chocolate-flavoured pellets on fixed ratio 1 (FR1), FR5 and progressive ratio (PR) schedule of reinforcement. No significant differences between genotypes were revealed on operant behaviour acquisition in FR1. DOR knockout mice displayed lower number of active lever-presses than wild-type mice on FR5, and a similar decrease was revealed in DOR KO mice in the breaking point during the PR. This operant training to obtain palatable food increased dendritic spine density in the PFC, HCP and NAc shell of wild-type, but these plasticity changes were abolished in DOR KO mice. Our results support the hypothesis that DOR regulates the reinforcing effects and motivation for palatable food through neuroplastic changes in specific brain reward areas., This work was supported by the DG Research of the European Commission FP7 (#HEALTH-F2 2013-602891), the Spanish ‘RETICS-Instituto de Salud Carlos III’ (#RD12/0028/0023), the Spanish ‘Ministerio de Ciencia e Innovación’ (#SAF2011-29864), the Spanish ‘Ministerio de Economia y Competitividad’ (#SAF-2014-59648P), the ‘Plan nacional sobre drogas’ (#PNSD-2013-5068) and the Catalan Government ‘AGAUR-Generalitat de Catalunya’ (#2009SGR00731 and #2014-SGR-1547). The FEDER funds support is also acknowledged. S.M. was supported by FI predoctoral fellowship of the Catalan Government; S.M-N. was supported by CAPES fellowship of the Brazilian Government (Programa Ciência Sem Froteiras). We thank Elysia James for invaluable technical assistance in the structural plasticity study
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids

  • Puighermanal Puigvert, Emma, 1983-
  • Busquets Garcia, Arnau, 1985-
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Exogenous cannabinoids, such as delta9-tetrahydrocannabinol (THC), as well as the modulation of endogenous cannabinoids, affect cognitive function through the activation of cannabinoid receptors. Indeed, these compounds modulate a number of signalling pathways critically implicated in the deleterious effect of cannabinoids on learning and memory. Thus, the involvement of the mammalian target of rapamycin pathway and extracellular signal-regulated kinases, together with their consequent regulation of cellular processes such as protein translation, play a critical role in the amnesic-like effects of cannabinoids. In this study, we summarize the cellular and molecular mechanisms reported in the modulation of cognitive function by the endocannabinoid system., EP is a recipient of an EMBO Fellowship with the support of European Commission (EMBOCOFUND2010, GA-2010-267146) and Marie Curie Actions. AB-G is a recipient of a predoctoral fellowship, Spanish Ministry of Education and Culture. This study was supported by grants from La Marató de TV3 (#090910 to AO), Grants from the Spanish Ministry of Science and Innovation (#SAF2009-07309 to AO and/n#SAF2011-29864 to RM); Instituto de Salud Carlos III (RD06/0001/0001 to RM); PLAN E (Plan Español para el Estímulo de la Economía y el Empleo); Generalitat de Catalunya (SGR-2009-00731 to RM and SGR-2009-00718 to RdlT); ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to RM
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Morphine-induced locomotor sensitization produces structural plasticity in the mesocorticolimbic system dependent on CB1-R activity

  • Guegan, Thomas, 1983-
  • Cebrià i Costa, Joan Pau, 1989-
  • Maldonado, Rafael, 1961-
  • Martín Sánchez, Miquel, 1971-
Changes in structural plasticity produced by the chronic exposure to drugs of abuse, such as alterations in dendritic spine densities, participate in the development of maladaptive learning processes leading to drug addiction. Understanding the neurobiological mechanisms involved in these aberrant changes is crucial to clarify the neurobiological substrate of addiction. Drug-induced locomotor sensitization has been widely accepted as a useful animal model to study these mechanisms related to drug addiction. We have evaluated the changes in structural plasticity in the mesocorticolimbic system involved in morphine-induced locomotor sensitization. The role of the cannabinoid receptor type 1 (CB1-R) in these neuroplastic alterations has also been studied using CB1-R-deficient (CB1-R KO) mice. Structural plasticity changes promoted by morphine are a highly dynamic phenomenon that evolves during the entire time course of the behavioral sensitization in wild-type (WT) animals. The different phases of the sensitization process were related to specific changes in connectivity between neurons revealed by modifications in dendritic spines in specific areas of the mesocorticolimbic system. Moreover, the lack of morphine-induced locomotor sensitization in CB1-R KO mice was accompanied by abnormal alterations in structural plasticity in the same mesocorticolimbic areas. These specific structural plasticity changes mediated by CB1-R activity seem necessary for the normal progression of morphine-induced locomotor sensitization and could play a critical role in the addictive process., This work was supported by European Commission-FP7 (#HEALTH-F2-2013-602891), RETICS-Instituto de Salud Carlos III (#RD12/0028/0023), MICINN-Ministerio de Ciencia e Innovación (#SAF2011-29864) and AGAUR-Generalitat de Catalunya (#2009SGR00731 and #2014-SGR-1547). FEDER co-funding is also acknowledged
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dissociation of the pharmacological effects of THC by mTOR blockade

  • Puighermanal Puigvert, Emma, 1983-
  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Marsicano, Giovanni
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
The potential therapeutic benefits of cannabinoid compounds have raised interest in understanding the molecular mechanisms that underlie cannabinoid-mediated effects. We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway. In the present study, we assess the relevance of the mTOR pathway in other acute and chronic pharmacological effects of THC. The rapamycin derivative temsirolimus, an inhibitor of the mTOR pathway approved by the Food and Drug Administration, prevents both the anxiogenic- and the amnesic-like effects produced by acute THC. In contrast, THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception are not sensitive to the mTOR inhibition. In addition, a clear tolerance to THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception was observed after chronic treatment, but not to its anxiogenic- and amnesic-like effects. Temsirolimus pre-treatment prevented the amnesic-like effects of chronic THC without affecting the downregulation of CB1 receptors (CB1R) induced by this chronic treatment. Instead, temsirolimus blockade after chronic THC cessation did not prevent the residual cognitive deficit produced by chronic THC. Using conditional knockout mice lacking CB1R in GABAergic or glutamatergic neurons, we found that GABAergic CB1Rs are mainly downregulated under chronic THC treatment conditions, and CB1-GABA-KO mice did not develop cognitive deficits after chronic THC exposure. Therefore, mTOR inhibition by temsirolimus allows the segregation of the potentially beneficial effects of cannabinoid agonists, such as the anxiolytic and antinociceptive effects, from the negative effects, such as anxiogenic- and amnesic-like responses. Altogether, these results provide new insights for targeting the endocannabinoid system in order to prevent possible side effects., EP and AB-G were recipients of a predoctoral fellowship, Ministerio de Educación y Cultura. This work was supported by grants from the Ministerio de Ciencia e Innovación (#SAF2009-07309 to AO and # SAF2011-29864 to RM), Instituto de Salud Carlos III (RD06/0001/0001 to RM), PLAN E/n(Plan Español para el Estímulo de la Economía y el Empleo), the European Commission/n(PHECOMP #LSHM-CT-2007-037669 to RM), Generalitat de Catalunya (SGR-2009-00731/nto RM), INSERM to GM, European Research Council (ENDOFOOD, ERC-2010-StG-/n260515, to GM), Fondation pour la Recherche Medicale to GM, and ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to RM
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure

  • Cutando Ruiz, Laura, 1985-
  • Busquets Garcia, Arnau, 1985-
  • Puighermanal Puigvert, Emma, 1983-
  • Gomis González, Maria, 1988-
  • Delgado García, José María
  • Gruart, Agnès
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Chronic cannabis exposure can lead to cerebellar dysfunction in humans, but the neurobiological mechanisms involved remain incompletely understood. Here, we found that in mice, subchronic administration of the psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), activated cerebellar microglia and increased the expression of neuroinflammatory markers, including IL-1β. This neuroinflammatory phenotype correlated with deficits in cerebellar conditioned learning and fine motor coordination. The neuroinflammatory phenotype was readily detectable in the cerebellum of mice with global loss of the CB1 cannabinoid receptor (CB1R, Cb1(-/-) mice) and in mice lacking CB1R in the cerebellar parallel fibers, suggesting that CB1R downregulation in the cerebellar molecular layer plays a key role in THC-induced cerebellar deficits. Expression of CB2 cannabinoid receptor (CB2R) and Il1b mRNA was increased under neuroinflammatory conditions in activated CD11b-positive microglial cells. Furthermore, administration of the immunosuppressant minocycline or an inhibitor of IL-1β receptor signaling prevented the deficits in cerebellar function in Cb1(-/-) and THC-withdrawn mice. Our results suggest that cerebellar microglial activation plays a crucial role in the cerebellar deficits induced by repeated cannabis exposure., This study was supported by grants from the Ministerio de Ciencia e Innovación (BFU2008-03390, to A. Gruart; BFU2008-00899, to J.M. Delgado-García; SAF2007-64062 and SAF2011-29864, to R. Maldonado; and SAF2009-07309 and BFU2012-33500, to A. Ozaita); the European Commission (PHECOMP, LSHM-CT-2007-037669, to R. Maldonado); the Instituto de Salud Carlos III (RTA-RETICS, RD06/001/001, to R. Maldonado); the Generalitat de Catalunya (SGR2009-SGR00731, to R. Maldonado); the Fundació La Marató de TV3 (090910, to A. Ozaita); and the ICREA Academia (to R. Maldonado). Partial support from the EU FEDER funds is also acknowledged.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far

  • Flores de los Heros, África, 1985-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
Emerging findings suggest the existence of a cross-talk between hypocretinergic and endocannabinoid systems. Although few studies have examined this relationship, the apparent overlap observed in the neuroanatomical distribution of both systems as well as their putative functions strongly point to the existence of such cross-modulation. In agreement, biochemical and functional studies have revealed the existence of heterodimers between CB1 cannabinoid receptor and hypocretin receptor-1, which modulates the cellular localization and downstream signaling of both receptors. Moreover, the activation of hypocretin receptor-1 stimulates the synthesis of 2-arachidonoyl glycerol culminating in the retrograde inhibition of neighboring cells and suggesting that endocannabinoids could contribute to some hypocretin effects. Pharmacological data indicate that endocannabinoids and hypocretins might have common physiological functions in the regulation of appetite, reward and analgesia. In contrast, these neuromodulatory systems seem to play antagonistic roles in the regulation of sleep/wake cycle and anxiety-like responses. The present review attempts to piece together what is known about this interesting interaction and describes its potential therapeutic implications., This work was supported by the Instituto de Salud CarlosIII grants, #PI07/0559, #PI10/00316 and #RD06/001/001 (RTA-RETICS), by the Spanish Ministry of Science and Technology, Consolider-C #SAF2007-64062 and #SAF2011-29864, the Catalan Government (SGR2009-00731), and by the Catalan Institution for Research and Advanced Studies (ICREA Academia program). África Flores is recipient of a predoctoral fellowship from the Spanish Ministry of Education
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Targeting the endocannabinoid system in the treatment of fragile X syndrome

  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Guegan, Thomas, 1983-
  • Agustín Pavón, Carmen
  • Pastor, Antonio
  • Mato, Susana
  • Pérez Samartín, A.
  • Matute, Carlos
  • Torre Fornell, Rafael de la
  • Dierssen, Mara
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Fragile X syndrome (FXS), the most common monogenic cause of inherited intellectual disability and autism, is caused by the silencing of the FMR1 gene, leading to the loss of fragile X mental retardation protein (FMRP), a synaptically expressed RNA-binding protein regulating translation. The Fmr1 knockout model recapitulates the main traits of the disease. Uncontrolled activity of metabotropic glutamate receptor 5 (mGluR5) and mammalian target of rapamycin (mTOR) signaling seem crucial in the pathology of this disease. The endocannabinoid system (ECS) is a key modulator of synaptic plasticity, cognitive performance, anxiety, nociception and seizure susceptibility, all of which are affected in FXS. The cannabinoid receptors CB1 (CB1R) and CB2 (CB2R) are activated by phospholipid-derived endocannabinoids, and CB1R-driven long-term regulation of synaptic strength, as a consequence of mGluR5 activation, is altered in several brain areas of Fmr1 knockout mice. We found that CB1R blockade in male Fmr1 knockout (Fmr1(-/y)) mice through pharmacological and genetic approaches normalized cognitive impairment, nociceptive desensitization, susceptibility to audiogenic seizures, overactivated mTOR signaling and altered spine morphology, whereas pharmacological blockade of CB2R normalized anxiolytic-like behavior. Some of these traits were also reversed by pharmacological inhibition of mTOR or mGluR5. Thus, blockade of ECS is a potential therapeutic approach to normalize specific alterations in FXS., This study was supported by grants from La Marató de TV3 (#090910 to AO), Grants from the Ministerio de Ciencia e Innovación (#SAF2009-07309 to AO, #SAF2011-29864 to RM and SAF2010-21547 to CM); Instituto de Salud Carlos III (RD06/0001/0001 to RM); PLAN E (Plan Español para el Estímulo de la Economía y el Empleo); Generalitat de Catalunya (SGR-2009-00731 to RM and SGR2009-00718 to RdlT); ICREA (Institució Catalana de Recerca i Estudis Avançats)/nAcademia to RM
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine

  • Navarrete, Francisco
  • Rodríguez Arias, Marta
  • Martín García, Elena, 1975-
  • Navarro, Daniela
  • García-Gutiérrez, Susana
  • Aguilar Morón, María Asunción
  • Aracil Fernández, Auxiliadora
  • Berbel, Pere
  • Miñarro, José
  • Maldonado, Rafael, 1961-
  • Manzanares, Jorge
This study was aimed to evaluate the involvement of CB2 cannabinoid receptors (CB2r) in the rewarding, reinforcing and motivational effects of nicotine. Conditioned place preference (CPP) and intravenous self-administration experiments were carried out in knockout mice lacking CB2r (CB2KO) and wild-type (WT) littermates treated with the CB2r antagonist AM630 (1 and 3 mg/kg). Gene expression analyses of tyrosine hydroxylase (TH) and α3- and α4-nicotinic acetylcholine receptor subunits (nAChRs) in the ventral tegmental area (VTA) and immunohistochemical studies to elucidate whether CB2r colocalized with α3- and α4-nAChRs in the nucleus accumbens and VTA were performed. Mecamylamine-precipitated withdrawal syndrome after chronic nicotine exposure was evaluated in CB2KO mice and WT mice treated with AM630 (1 and 3 mg/kg). CB2KO mice did not show nicotine-induced place conditioning and self-administered significantly less nicotine. In addition, AM630 was able to block (3 mg/kg) nicotine-induced CPP and reduce (1 and 3 mg/kg) nicotine self-administration. Under baseline conditions, TH, α3-nAChR, and α4-nAChR mRNA levels in the VTA of CB2KO mice were significantly lower compared with WT mice. Confocal microscopy images revealed that CB2r colocalized with α3- and α4-nAChRs. Somatic signs of nicotine withdrawal (rearings, groomings, scratches, teeth chattering, and body tremors) increased significantly in WT but were absent in CB2KO mice. Interestingly, the administration of AM630 blocked the nicotine withdrawal syndrome and failed to alter basal behavior in saline-treated WT mice. These results suggest that CB2r play a relevant role in the rewarding, reinforcing, and motivational effects of nicotine. Pharmacological manipulation of this receptor deserves further consideration as a potential new valuable target for the treatment of nicotine dependence., This study was supported by the following research grants: Ministerio de Ciencia e Innovación (SAF2011-23420 to Jorge Manzanares, SAF2009-10689 to Pere Berbel, and SAF2011-29864 to Rafael Maldonado); Ministerio de Economía y Competitividad, Dirección General de Investigación (PSI2011-24762) to José Miñarro; Generalidad Valenciana, Consejería de Educación (PROMETEO/2009/072) to José Miñarro; Gobierno Catalán (SGR2009-00131) to Rafael Maldonado; ICREA Academia-2008 to Rafael Maldonado; and Instituto de Salud ‘Carlos III’ (FIS), RETICS, Red de Trastornos Adictivos (RD06/0001/1004, RD12/0028/0019 to Jorge Manzanares; RD06/001/0016, RD12/0028/005 to José Miarro; RD06/001/001, RD12/0028/0023 to Rafael Maldonado)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The hypocretin/orexin system mediates the extinction of fear memories

  • Flores de los Heros, África, 1985-
  • Valls Comamala, Victòria, 1987-
  • Costa, Giulia
  • Saravia Santos, Rocio, 1988-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
Anxiety disorders are often associated with an inability to extinguish learned fear responses. The hypocretin/orexin system is involved in the regulation of emotional states and could also participate in the consolidation and extinction of aversive memories. Using hypocretin receptor-1 and hypocretin receptor-2 antagonists, hypocretin-1 and hypocretin-2 peptides, and hypocretin receptor-1 knockout mice, we investigated the role of the hypocretin system in cue- and context-dependent fear conditioning and extinction. Hypocretins were crucial for the consolidation of fear conditioning, and this effect was mainly observed in memories with a high emotional component. Notably, after the acquisition of fear memory, hypocretin receptor-1 blockade facilitated fear extinction, whereas hypocretin-1 administration impaired this extinction process. The extinction-facilitating effects of the hypocretin receptor-1 antagonist SB334867 were associated with increased expression of cFos in the basolateral amygdala and the infralimbic cortex. Intra-amygdala, but neither intra-infralimbic prefrontal cortex nor intra-dorsohippocampal infusion of SB334867 enhanced fear extinction. These results reveal a key role for hypocretins in the extinction of aversive memories and suggest that hypocretin receptor-1 blockade could represent a novel therapeutic target for the treatment of diseases associated with inappropriate retention of fear, such as post-traumatic stress disorder and phobias., This work was supported by the Instituto de Salud Carlos III grants, #PI13/00042 and #RD12/0028/0023 (RTA-RETICS), by the Spanish Ministry of Science #SAF2011-29864, the/nCatalan Government (SGR2009-00731), and by the Catalan Institution for Research and Advanced Studies (ICREA Academia program). África Flores is a recipient of a predoctoral fellowship from the Spanish Ministry of Education.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9)-tetrahydrocannabinol

  • Flores de los Heros, África, 1985-
  • Julià Hernández, Marina
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
BACKGROUND AND PURPOSE: Anatomical, biochemical and pharmacological evidence suggest the existence of a crosstalk between the orexinergic and endocannabinoid systems. While the orexin receptor 1 (OX1 receptor) modulates the reinforcing properties of cannabinoids, the participation of orexins in the acute pharmacological effects of Δ(9) -tetrahydrocannabinol (THC) remains unexplored. EXPERIMENTAL APPROACH: We assessed the possible role of orexins in THC-induced hypolocomotion, hypothermia, antinociception, anxiolytic- and anxiogenic-like effects and memory impairment. Selective OX1 and OX2 receptor antagonists and OX1 knockout (KO) mice as well as prepro-orexin (PPO) KO mice were used as pharmacological and genetic approaches. CB1 receptor levels in control and PPO KO mice were evaluated by immunoblot analysis. The expression of c-Fos after THC treatment was analysed in several brain areas in wild-type mice and in mice lacking the PPO gene. KEY RESULTS: The hypothermia, supraspinal antinociception and anxiolytic-like effects induced by THC were modulated by orexins through OX2 receptor signalling. OX1 receptors did not seem to be involved in these THC responses. No differences in CB1 receptor levels were found between wild-type and PPO KO mice. THC-induced increase in c-Fos expression was reduced in the central amygdala, medial preoptic area and lateral septum in these mutant mice. CONCLUSIONS AND IMPLICATIONS: Our results provide new findings to further clarify the interaction between orexins and cannabinoids. OX1 and OX2 receptors are differently implicated in the pharmacological effects of cannabinoids., This work was supported by the Instituto de Salud Carlos III grants [#PI13/00042 and #RD12/0028/0023 (RTA-RETICS)], by the Spanish Ministry of Science (#SAF2011-29864 and #SAF2014-59648-P), National Plan on Drugs (#2014I019) and the Catalan Government (SGR2014-1547)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain

  • La Porta, Carmen, 1985-
  • Bura, S. Andreea, 1978-
  • Llorente Onaindia, Jone
  • Pastor, Antonio
  • Navarrete, Francisco
  • García-Gutiérrez, María S.
  • Torre Fornell, Rafael de la
  • Manzanares, Jorge
  • Monfort, Jordi
  • Maldonado, Rafael, 1961-
In this study, we investigated the role of the endocannabinoid system (ECS) in the emotional and cognitive alterations associated with osteoarthritis pain. The monosodium iodoacetate model was used to evaluate the affective and cognitive manifestations of osteoarthritis pain in type 1 (CB1R) and type 2 (CB2R) cannabinoid receptor knockout and wild-type mice and the ability of CB1R (ACEA) and CB2R (JWH133) selective agonists to improve these manifestations during a 3-week time period. The levels of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were measured in plasma and brain areas involved in the control of these manifestations. Patients with knee osteoarthritis and healthy controls were recruited to evaluate pain, affective, and cognitive symptoms, as well as plasma endocannabinoid levels and cannabinoid receptor gene expression in peripheral blood lymphocytes. The affective manifestations of osteoarthritis were enhanced in CB1R knockout mice and absent in CB2R knockouts. Interestingly, both ACEA and JWH133 ameliorated the nociceptive and affective alterations, whereas ACEA also improved the associated memory impairment. An increase of 2-AG levels in prefrontal cortex and plasma was observed in this mouse model of osteoarthritis. In agreement, an increase of 2-AG plasmatic levels and an upregulation of CB1R and CB2R gene expression in peripheral blood lymphocytes were observed in patients with osteoarthritis compared with healthy subjects. Changes found in these biomarkers of the ECS correlated with pain, affective, and cognitive symptoms in these patients. The ECS plays a crucial role in osteoarthritis and represents an interesting pharmacological target and biomarker of this disease., This work was supported by European Commission-FP7 (#HEALTH-F2-2013-602891), RETICS-Instituto de Salud Carlos III (#RD12/0028/0023), MICINN-Ministerio de Ciencia e Innovación (#SAF2011-29864), AGAUR-Generalitat de Catalunya (#2009SGR00731), #2014-SGR-680 and #2014-SGR-1547). ISCIII-FIS-CAIBER (CAI08/01/0024), CIBEROBN (CB06/03/0028). CIBEROBN is an initiative of Instituto de Salud Carlos III, Madrid, Spain. FEDER co-funding is also acknowledged.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Orexins and fear: implications for the treatment of anxiety disorders

  • Flores de los Heros, África, 1985-
  • Saravia Santos, Rocio, 1988-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
An understanding of the neurobiological mechanisms involved in the regulation of fear is essential for the development of new treatments for anxiety disorders, such as phobias, panic, and post-traumatic stress disorders (PTSD). Orexins, also known as hypocretins, are neuropeptides located exclusively in hypothalamic neurons that have extensive projections throughout the central nervous system. Although this system was initially believed to be primarily involved in the regulation of feeding behavior, recent studies have shown that orexins also modulate neural circuits implicated in the expression and extinction of fear memories. Here, we discuss recent findings involving orexins in anxiety disorders and current clinical trials using orexin ligands that could be applied to identify new therapies for diseases characterized by pathological fear., This work was supported by the Instituto de Salud Carlos III grants, #PI13/00042 and #RD12/0028/0023 (RTA-RETICS), by the Spanish Ministry of Science #SAF2011-29864 and #SAF2014-59648-P, National Plan on Drugs #2014I019, and the Catalan Government (SGR2014-1547).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Baclofen and 2-hydroxysaclofen modify acute hypolocomotive and antinociceptive effects of nicotine

  • Varani, Andrés P.
  • Aso Pérez, Ester
  • Maldonado, Rafael, 1961-
  • Balerio, Graciela N.
The aim of the present study was to evaluate the possible involvement of GABAB receptors in nicotine-induced hypolocomotion and antinociceptive effects in mice. Animals were exposed to nicotine only once. Acute nicotine hydrogen tartrate salt (3mg/kg; subcutaneous, s.c.) administration induced hypolocomotion and antinociceptive responses in the tail-immersion and the hot-plate tests. The effects of pretreatment with either the GABAB receptor agonist baclofen (1, 2 and 3mg/kg; intraperitoneal, i.p.) or GABAB receptor antagonist 2-hydroxysaclofen (0.25, 0.5 and 1mg/kg; i.p.) were evaluated on these behavioral nicotine responses. The GABAB receptor agonist, baclofen (3mg/kg, i.p.) abolished nicotine-induced antinociceptive effects in the tail-immersion and the hot-plate tests, but did not modify nicotine-induced hypolocomotion. In addition, the GABAB receptor antagonist, 2-hydroxysaclofen (1mg/kg, i.p.) increased nicotine-induced antinociceptive effects in the tail-immersion and the hot-plate tests, and abolished nicotine-induced hypolocomotion. The present results shed light that the GABAB receptor has an important role in mediating specific acute nicotine responses such as hypolocomotion and antinociception in mice., This work has been supported by grants from University of Buenos Aires (UBACyT B016 and UBACyT 2013–2016 No. 20020120100244), CONICET (PIP 11420090100303), Spanish “Ministerio de Ciencia e Innovación” (#SAF2011-29864), “Instituto de Salud Carlos III” (RETICS: #RD06/0001/0001, #RD06/0001/1004), Plan Nacional sobre Drogas (PNSD #2009/026), the Catalan Government (SGR2009-00131) and the ICREA Foundation (ICREA Academia-2008)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model

  • Busquets Garcia, Arnau, 1985-
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Fragile X syndrome is the most common monogenetic form of intellectual disability and is a leading cause of autism. This syndrome is produced by the reduced transcription of the fragile X mental retardation (FMR1) gene, and it is characterized by a range of symptoms heterogeneously expressed in patients such as cognitive impairment, seizure susceptibility, altered pain sensitivity and anxiety. The recent advances in the understanding of the pathophysiological mechanisms involved have opened novel potential therapeutic approaches identified in preclinical rodent models as a necessary preliminary step for the subsequent evaluation in patients. Among those possible therapeutic approaches, the modulation of the metabotropic glutamate receptor signaling or the GABA receptor signaling have focused most of the attention. New findings in the animal models open other possible therapeutic approaches such as the mammalian target of rapamycin signaling pathway or the endocannabinoid system. This review summarizes the emerging data recently obtained in preclinical models of fragile X syndrome supporting these new therapeutic perspectives., AB-G was recipient of a predoctoral fellowship (Ministerio de Educación y Cultura) and supported by “Investments for the future” Programme IdEx Bordeaux (ANR-10-IDEX-03-02, French National Research Agency). Related research on the subject was supported by grants from FRAXA Research Foundation (A.O.), Jérôme Lejeune Foundation (A.O.), Ministerio de Ciencia e Innovación (#BFU2012-33500 to A.O., #SAF2011-29864 to R.M.); Instituto de Salud Carlos III (RD06/0001/0001 to R.M.); PLAN E (Plan Español para el Estímulo de la Economía y el Empleo); Generalitat de Catalunya (SGR-2009-00731 to R.M.); ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to R.M.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure

  • Cutando Ruiz, Laura, 1985-
  • Busquets Garcia, Arnau, 1985-
  • Puighermanal Puigvert, Emma, 1983-
  • Gomis González, Maria, 1988-
  • Delgado García, José María
  • Gruart, Agnès
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Chronic cannabis exposure can lead to cerebellar dysfunction in humans, but the neurobiological mechanisms involved remain incompletely understood. Here, we found that in mice, subchronic administration of the psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), activated cerebellar microglia and increased the expression of neuroinflammatory markers, including IL-1β. This neuroinflammatory phenotype correlated with deficits in cerebellar conditioned learning and fine motor coordination. The neuroinflammatory phenotype was readily detectable in the cerebellum of mice with global loss of the CB1 cannabinoid receptor (CB1R, Cb1(-/-) mice) and in mice lacking CB1R in the cerebellar parallel fibers, suggesting that CB1R downregulation in the cerebellar molecular layer plays a key role in THC-induced cerebellar deficits. Expression of CB2 cannabinoid receptor (CB2R) and Il1b mRNA was increased under neuroinflammatory conditions in activated CD11b-positive microglial cells. Furthermore, administration of the immunosuppressant minocycline or an inhibitor of IL-1β receptor signaling prevented the deficits in cerebellar function in Cb1(-/-) and THC-withdrawn mice. Our results suggest that cerebellar microglial activation plays a crucial role in the cerebellar deficits induced by repeated cannabis exposure., This study was supported by grants from the Ministerio de Ciencia e Innovación (BFU2008-03390, to A. Gruart; BFU2008-00899, to J.M. Delgado-García; SAF2007-64062 and SAF2011-29864, to R. Maldonado; and SAF2009-07309 and BFU2012-33500, to A. Ozaita); the European Commission (PHECOMP, LSHM-CT-2007-037669, to R. Maldonado); the Instituto de Salud Carlos III (RTA-RETICS, RD06/001/001, to R. Maldonado); the Generalitat de Catalunya (SGR2009-SGR00731, to R. Maldonado); the Fundació La Marató de TV3 (090910, to A. Ozaita); and the ICREA Academia (to R. Maldonado). Partial support from the EU FEDER funds is also acknowledged.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Role of DOR in neuronal plasticity changes promoted by food-seeking behaviour

  • Mancino, Samantha, 1987-
  • Mendonça Netto, Sueli
  • Martín García, Elena, 1975-
  • Maldonado, Rafael, 1961-
Several lines of evidence support that food overconsumption may be related to the role of the endogenous opioid system in the control of food palatability. The opioid system, and particularly the delta opioid receptor (DOR), plays a crucial role in the regulation of food rewarding properties. In our study, we used operant conditioning maintained by chocolate-flavoured pellets to investigate the role of DOR in the motivation for palatable food and the structural plasticity changes promoted by this behaviour. For this purpose, we evaluated the specific role of this receptor in the behavioural and neuroplastic changes induced by palatable food in the prefrontal cortex (PFC), hippocampus (HCP) and nucleus accumbens (NAc) in constitutive knockout (KO) mice deficient in DOR. Mutant mice and their wild-type littermates were trained to obtain chocolate-flavoured pellets on fixed ratio 1 (FR1), FR5 and progressive ratio (PR) schedule of reinforcement. No significant differences between genotypes were revealed on operant behaviour acquisition in FR1. DOR knockout mice displayed lower number of active lever-presses than wild-type mice on FR5, and a similar decrease was revealed in DOR KO mice in the breaking point during the PR. This operant training to obtain palatable food increased dendritic spine density in the PFC, HCP and NAc shell of wild-type, but these plasticity changes were abolished in DOR KO mice. Our results support the hypothesis that DOR regulates the reinforcing effects and motivation for palatable food through neuroplastic changes in specific brain reward areas., This work was supported by the DG Research of the European Commission FP7 (#HEALTH-F2 2013-602891), the Spanish ‘RETICS-Instituto de Salud Carlos III’ (#RD12/0028/0023), the Spanish ‘Ministerio de Ciencia e Innovación’ (#SAF2011-29864), the Spanish ‘Ministerio de Economia y Competitividad’ (#SAF-2014-59648P), the ‘Plan nacional sobre drogas’ (#PNSD-2013-5068) and the Catalan Government ‘AGAUR-Generalitat de Catalunya’ (#2009SGR00731 and #2014-SGR-1547). The FEDER funds support is also acknowledged. S.M. was supported by FI predoctoral fellowship of the Catalan Government; S.M-N. was supported by CAPES fellowship of the Brazilian Government (Programa Ciência Sem Froteiras). We thank Elysia James for invaluable technical assistance in the structural plasticity study
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors.

  • Viñals Álvarez, Xavier, 1985-
  • Moreno, Estefanía
  • Lanfumey, Laurence
  • Cordomí, Arnau
  • Pastor, Antonio
  • Torre Fornell, Rafael de la
  • Gasperini, Paola
  • Navarro, Gemma
  • Howell, Lesley A.
  • Pardo, Leonardo
  • Lluís, Carmen
  • Canela, Enric I.
  • McCormick, Peter J.
  • Maldonado, Rafael, 1961-
  • Robledo, Patricia, 1958-
Activation of cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) produces a variety of negative effects with major consequences in cannabis users that constitute important drawbacks for the use of cannabinoids as therapeutic agents. For this reason, there is a tremendous medical interest in harnessing the beneficial effects of THC. Behavioral studies carried out in mice lacking 5-HT2A receptors (5-HT2AR) revealed a remarkable 5-HT2AR-dependent dissociation in the beneficial antinociceptive effects of THC and its detrimental amnesic properties. We found that specific effects of THC such as memory deficits, anxiolytic-like effects, and social interaction are under the control of 5-HT2AR, but its acute hypolocomotor, hypothermic, anxiogenic, and antinociceptive effects are not. In biochemical studies, we show that CB1R and 5-HT2AR form heteromers that are expressed and functionally active in specific brain regions involved in memory impairment. Remarkably, our functional data shows that costimulation of both receptors by agonists reduces cell signaling, antagonist binding to one receptor blocks signaling of the interacting receptor, and heteromer formation leads to a switch in G-protein coupling for 5-HT2AR from Gq to Gi proteins. Synthetic peptides with the sequence of transmembrane helices 5 and 6 of CB1R, fused to a cell-penetrating peptide, were able to disrupt receptor heteromerization in vivo, leading to a selective abrogation of memory impairments caused by exposure to THC. These data reveal a novel molecular mechanism for the functional interaction between CB1R and 5-HT2AR mediating cognitive impairment. CB1R-5-HT2AR heteromers are thus good targets to dissociate the cognitive deficits induced by THC from its beneficial antinociceptive properties., This study was supported by grants from the Spanish ‘Ministerio de Ciencia e Innovación’ (SAF2011-29864) to RM, SAF2010-18472) to PJM and (SAF2011-23813) to EC. ‘Ministerio de Economía y Competitividad’ (SAF2014-59648-P) to RM. The Spanish ‘Instituto de Salud Carlos III’ (P1070709 and PI14/00210) to PR and (RD06/001/ 001) to RM, the Catalan government (SGR2009- 00131) to RM. PJM was supported by a Ramon y Cajal Fellow and internal funds from UEA, and PJM and LP participate in the European COST Action CM 1207 (GLISTEN). FEDER funds partial support is also acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior

  • Plaza-Zabala, Ainhoa, 1982-
  • Flores de los Heros, África, 1985-
  • Martín García, Elena, 1975-
  • Saravia Santos, Rocio, 1988-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
Hypocretin/orexin signaling is critically involved in relapse to drug-seeking behaviors. In this study, we investigated the involvement of the hypocretin system in the reinstatement of nicotine-seeking behavior induced by nicotine-associated cues. Pretreatment with the hypocretin receptor-1 antagonist SB334867, but not with the hypocretin receptor-2 antagonist TCSOX229, attenuated cue-induced reinstatement of nicotine-seeking, which was associated with an activation of hypocretin neurons of the lateral and perifornical hypothalamic areas. In addition, relapse to nicotine-seeking increased the phosphorylation levels of GluR2-Ser880, NR1-Ser890, and p38 MAPK in the nucleus accumbens (NAc), but not in the prefrontal cortex. Notably, phosphorylation levels of NR1-Ser890 and p38 MAPK, but not GluR2-Ser880, were dependent on hypocretin receptor-1 activation. The intra-accumbens infusion of the protein kinase C (PKC) inhibitor NPC-15437 reduced nicotine-seeking behavior elicited by drug-paired cues consistent with the PKC-dependent phosphorylations of GluR2-Ser880 and NR1-Ser890. SB334867 failed to modify cue-induced reinstatement of food-seeking, which did not produce any biochemical changes in the NAc. These data identify hypocretin receptor-1 and PKC signaling as potential targets for the treatment of relapse to nicotine-seeking induced by nicotine-associated cues., This work was supported by the Instituto de Salud Carlos III grants, #PI07/0559, #PI10/00316 and #RD06/001/001 (RTA-RETICS), by the Spanish Ministry of Science and Technology, Consolider-C #SAF2007-64062 and #SAF2011-29864, the Catalan Government (SGR2009-00731), and by the Catalan Institution for Research and Advanced Studies (ICREA Academia program). Ainhoa Plaza-Zabala and África Flores are recipients of a predoctoral fellowship from the Spanish Ministry of Education
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Endocannabinoid system and drug addiction: new insights from mutant mice approaches

  • Maldonado, Rafael, 1961-
  • Robledo, Patricia, 1958-
  • Berrendero Díaz, Fernando, 1971-
The involvement of the endocannabinoid system in drug addiction was initially studied by the use of compounds with different affinities for each cannabinoid receptor or for the proteins involved in endocannabinoids inactivation. The generation of genetically modified mice with selective mutations in these endocannabinoid system components has now provided important advances in establishing their specific contribution to drug addiction. These genetic tools have identified the particular interest of CB1 cannabinoid receptor and endogenous anandamide as potential targets for drug addiction treatment. Novel genetic tools will allow determining if the modulation of CB2 cannabinoid receptor activity and 2-arachidonoylglycerol tone can also have an important therapeutic relevance for drug addiction., This work was supported by the Spanish “Ministerio de Ciencia e Innovación” (#SAF2007-64062 and SAF2011-29864), “Instituto de Salud Carlos III” (RETICS- Red de Trastornos Adictivos-Redes Temáticas de Investigación Cooperativa en Salud: #RD06/0001/0001, #RD06/0001/1004), grants #10/00316 and #10/01708, Plan Nacional sobre Drogas (PNSD #2009/026), the Catalan Government (SGR2009-00131) and the ICREA Foundation (ICREA Academia-2008)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine

  • Navarrete, Francisco
  • Rodríguez Arias, Marta
  • Martín García, Elena, 1975-
  • Navarro, Daniela
  • García-Gutiérrez, Susana
  • Aguilar Morón, María Asunción
  • Aracil Fernández, Auxiliadora
  • Berbel, Pere
  • Miñarro, José
  • Maldonado, Rafael, 1961-
  • Manzanares, Jorge
This study was aimed to evaluate the involvement of CB2 cannabinoid receptors (CB2r) in the rewarding, reinforcing and motivational effects of nicotine. Conditioned place preference (CPP) and intravenous self-administration experiments were carried out in knockout mice lacking CB2r (CB2KO) and wild-type (WT) littermates treated with the CB2r antagonist AM630 (1 and 3 mg/kg). Gene expression analyses of tyrosine hydroxylase (TH) and α3- and α4-nicotinic acetylcholine receptor subunits (nAChRs) in the ventral tegmental area (VTA) and immunohistochemical studies to elucidate whether CB2r colocalized with α3- and α4-nAChRs in the nucleus accumbens and VTA were performed. Mecamylamine-precipitated withdrawal syndrome after chronic nicotine exposure was evaluated in CB2KO mice and WT mice treated with AM630 (1 and 3 mg/kg). CB2KO mice did not show nicotine-induced place conditioning and self-administered significantly less nicotine. In addition, AM630 was able to block (3 mg/kg) nicotine-induced CPP and reduce (1 and 3 mg/kg) nicotine self-administration. Under baseline conditions, TH, α3-nAChR, and α4-nAChR mRNA levels in the VTA of CB2KO mice were significantly lower compared with WT mice. Confocal microscopy images revealed that CB2r colocalized with α3- and α4-nAChRs. Somatic signs of nicotine withdrawal (rearings, groomings, scratches, teeth chattering, and body tremors) increased significantly in WT but were absent in CB2KO mice. Interestingly, the administration of AM630 blocked the nicotine withdrawal syndrome and failed to alter basal behavior in saline-treated WT mice. These results suggest that CB2r play a relevant role in the rewarding, reinforcing, and motivational effects of nicotine. Pharmacological manipulation of this receptor deserves further consideration as a potential new valuable target for the treatment of nicotine dependence., This study was supported by the following research grants: Ministerio de Ciencia e Innovación (SAF2011-23420 to Jorge Manzanares, SAF2009-10689 to Pere Berbel, and SAF2011-29864 to Rafael Maldonado); Ministerio de Economía y Competitividad, Dirección General de Investigación (PSI2011-24762) to José Miñarro; Generalidad Valenciana, Consejería de Educación (PROMETEO/2009/072) to José Miñarro; Gobierno Catalán (SGR2009-00131) to Rafael Maldonado; ICREA Academia-2008 to Rafael Maldonado; and Instituto de Salud ‘Carlos III’ (FIS), RETICS, Red de Trastornos Adictivos (RD06/0001/1004, RD12/0028/0019 to Jorge Manzanares; RD06/001/0016, RD12/0028/005 to José Miarro; RD06/001/001, RD12/0028/0023 to Rafael Maldonado)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting the endocannabinoid system in the treatment of fragile X syndrome

  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Guegan, Thomas, 1983-
  • Agustín Pavón, Carmen
  • Pastor, Antonio
  • Mato, Susana
  • Pérez Samartín, A.
  • Matute, Carlos
  • Torre Fornell, Rafael de la
  • Dierssen, Mara
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Fragile X syndrome (FXS), the most common monogenic cause of inherited intellectual disability and autism, is caused by the silencing of the FMR1 gene, leading to the loss of fragile X mental retardation protein (FMRP), a synaptically expressed RNA-binding protein regulating translation. The Fmr1 knockout model recapitulates the main traits of the disease. Uncontrolled activity of metabotropic glutamate receptor 5 (mGluR5) and mammalian target of rapamycin (mTOR) signaling seem crucial in the pathology of this disease. The endocannabinoid system (ECS) is a key modulator of synaptic plasticity, cognitive performance, anxiety, nociception and seizure susceptibility, all of which are affected in FXS. The cannabinoid receptors CB1 (CB1R) and CB2 (CB2R) are activated by phospholipid-derived endocannabinoids, and CB1R-driven long-term regulation of synaptic strength, as a consequence of mGluR5 activation, is altered in several brain areas of Fmr1 knockout mice. We found that CB1R blockade in male Fmr1 knockout (Fmr1(-/y)) mice through pharmacological and genetic approaches normalized cognitive impairment, nociceptive desensitization, susceptibility to audiogenic seizures, overactivated mTOR signaling and altered spine morphology, whereas pharmacological blockade of CB2R normalized anxiolytic-like behavior. Some of these traits were also reversed by pharmacological inhibition of mTOR or mGluR5. Thus, blockade of ECS is a potential therapeutic approach to normalize specific alterations in FXS., This study was supported by grants from La Marató de TV3 (#090910 to AO), Grants from the Ministerio de Ciencia e Innovación (#SAF2009-07309 to AO, #SAF2011-29864 to RM and SAF2010-21547 to CM); Instituto de Salud Carlos III (RD06/0001/0001 to RM); PLAN E (Plan Español para el Estímulo de la Economía y el Empleo); Generalitat de Catalunya (SGR-2009-00731 to RM and SGR2009-00718 to RdlT); ICREA (Institució Catalana de Recerca i Estudis Avançats)/nAcademia to RM
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A novel anxiogenic role for the delta opioid receptor expressed in GABAergic forebrain neurons

  • Chung, Paul Chu Sin
  • Keyworth, Helen L.
  • Martín García, Elena, 1975-
  • Charbogne, Pauline
  • Darcq, Emmanuel
  • Bailey, Alexis
  • Filliol, Dominique
  • Matifas, Audrey
  • Scherrer, Grégory
  • Ouagazzal, Abdel-Mouttalib
  • Gaveriaux-Ruff, Claire
  • Befort, Katia
  • Maldonado, Rafael, 1961-
  • Kitchen, Ian
  • Kieffer, Brigitte L.
BACKGROUND: The delta opioid receptor (DOR) is broadly expressed throughout the nervous system; it regulates chronic pain, emotional responses, motivation, and memory. Neural circuits underlying DOR activities have been poorly explored by genetic approaches. We used conditional mouse mutagenesis to elucidate receptor function in GABAergic neurons of the forebrain. METHODS: We characterized DOR distribution in the brain of Dlx5/6-CreXOprd1(fl/fl) (Dlx-DOR) mice and tested main central DOR functions through behavioral testing. RESULTS: The DOR proteins were strongly deleted in olfactory bulb and striatum and remained intact in cortex and basolateral amygdala. Olfactory perception, circadian activity, and despair-like behaviors were unchanged. In contrast, locomotor stimulant effects of SNC80 (DOR agonist) and SKF81297 (D1 agonist) were abolished and increased, respectively. The Dlx-DOR mice showed lower levels of anxiety in the elevated plus maze, opposing the known high anxiety in constitutive DOR knockout animals. Also, Dlx-DOR mice reached the food more rapidly in a novelty suppressed feeding task, despite their lower motivation for food reward observed in an operant paradigm. Finally, c-fos protein staining after novelty suppressed feeding was strongly reduced in amygdala, concordant with the low anxiety phenotype of Dlx-DOR mice. CONCLUSIONS: We demonstrate that DORs expressed in the forebrain mediate the described locomotor effect of SNC80 and inhibit D1-stimulated hyperactivity. Our data also reveal an unanticipated anxiogenic role for this particular DOR subpopulation, with a potential novel adaptive role. In emotional responses, DORs exert dual anxiolytic and anxiogenic roles, both of which may have implications in the area of anxiety disorders., This work was supported by the Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, and Université de Strasbourg; the Fondation pour la Recherche Médicale (Grant No. FRM FDT20120925269), the U.S. National Institutes of Health (National Institute of Drug Addiction, Grant No. 05010, and National Institute on Alcohol Abuse and Alcoholism, Grant No. 16658); the Spanish Instituto de Salud Carlos III (Red de Trastornos Adictivos, Grant No. RD06/001/001), the Spanish Ministerio de Ciencia e Innovación (No. Ministerio de Ciencia e Innovación [Grant No. SAF2011-29864]), the Catalan Government (Grant No. SGR2009-00131), and Institucio Catalana de Recerca i Estudis Avançats Academia-2008; and NeuroPain (Framework programme 7, European Union)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenetic and proteomic expression changes promoted by eating addictive-like behavior

  • Mancino, Samantha, 1987-
  • Burokas, Aurelijus, 1982-
  • Gutiérrez Cuesta, Javier
  • Gutiérrez Martos, Miriam, 1989-
  • Martín García, Elena, 1975-
  • Pucci, Mariangela
  • Falconi, Anastasia
  • D'Addario, Claudio
  • Maccarrone, Mauro
  • Maldonado, Rafael, 1961-
An increasing perspective conceptualizes obesity and overeating as disorders related to addictive-like processes that could share common neurobiological mechanisms. In the present study, we aimed at validating an animal model of eating addictive-like behavior in mice, based on the DSM-5 substance use disorder criteria, using operant conditioning maintained by highly palatable chocolate-flavored pellets. For this purpose, we evaluated persistence of food-seeking during a period of non-availability of food, motivation for food, and perseverance of responding when the reward was associated with a punishment. This model has allowed identifying extreme subpopulations of mice related to addictive-like behavior. We investigated in these subpopulations the epigenetic and proteomic changes. A significant decrease in DNA methylation of CNR1 gene promoter was revealed in the prefrontal cortex of addict-like mice, which was associated with an upregulation of CB1 protein expression in the same brain area. The pharmacological blockade (rimonabant 3 mg/kg; i.p.) of CB1 receptor during the late training period reduced the percentage of mice that accomplished addiction criteria, which is in agreement with the reduced performance of CB1 knockout mice in this operant training. Proteomic studies have identified proteins differentially expressed in mice vulnerable or not to addictive-like behavior in the hippocampus, striatum, and prefrontal cortex. These changes included proteins involved in impulsivity-like behavior, synaptic plasticity, and cannabinoid signaling modulation, such as alpha-synuclein, phosphatase 1-alpha, doublecortin-like kinase 2, and diacylglycerol kinase zeta, and were validated by immunoblotting. This model provides an excellent tool to investigate the neurobiological substrate underlying the vulnerability to develop eating addictive-like behavior., This work was supported by the DG Research of the European Commission FP7 (No. HEALTH-F2 2013-602891), the Spanish ‘RETICS-Instituto de Salud Carlos III’ (No. RD12/0028/0023), the Spanish ‘Ministerio de Ciencia e Innovación’ (No. SAF2011-29864), and the Catalan Government ‘AGAUR-Generalitat de Catalunya’ (Nos. 2009SGR00731 and 2014-SGR-1547). The FEDER funds support is also acknowledged. SM and AB were supported by FI predoctoral fellowships of the Catalan Government, and JG-C was supported by a ‘Juan de la Cierva’ postdoctoral fellowship from the Spanish ‘Ministerio de Ciencia e Innovación’. Also support by the Italian Ministry of University and Research under grants FIRB-RBFR12DELS to CDA and PRIN2010-11 to MM is gratefully acknowledged. The authors declare no conflict of interest.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Looking for prosocial genes: ITRAQ analysis of proteins involved in MDMA-induced sociability in mice

  • Kuteykin-Teplyakov, Konstantin
  • Maldonado, Rafael, 1961-
Social behavior plays a fundamental role in life of many animal species, allowing the interaction between individuals and sharing of experiences, needs, and goals across them. In humans, some neuropsychiatric diseases, including anxiety, posttraumatic stress disorder and autism spectrum disorders, are often characterized by impaired sociability. Here we report that N-Methyl-3,4-methylenedioxyamphetamine (MDMA, "Ecstasy") at low dose (3mg/kg) has differential effects on mouse social behavior. In some animals, MDMA promotes sociability without hyperlocomotion, whereas in other mice it elevates locomotor activity without affecting sociability. Both WAY-100635, a selective antagonist of 5-HT1A receptor, and L-368899, a selective oxytocin receptor antagonist, abolish prosocial effects of MDMA. Differential quantitative analysis of brain proteome by isobaric tag for relative and absolute quantification technology (iTRAQ) revealed 21 specific proteins that were highly correlated with sociability, and allowed to distinguish between entactogenic prosocial and hyperlocomotor effects of MDMA on proteome level. Our data suggest particular relevance of neurotransmission mediated by GABA B receptor, as well as proteins involved in energy maintenance for MDMA-induced sociability. Functional association network for differentially expressed proteins in cerebral cortex, hippocampus and amygdala were identified. These results provide new information for understanding the neurobiological substrate of sociability and may help to discover new therapeutic approaches to modulate social behavior in patients suffering from social fear and low sociability., This work was supported by the Spanish “Ministerio de Ciencia e Innovación” (SAF2011-29864); Spanish “Instituto de Salud Carlos III” (RETICS – Red de Trastornos Adictivos – Redes Temáticas de Investigación Cooperativa en Salud: #RD06/0001/0001, #RD06/0001/1004); Spanish “Plan Nacional sobre Drogas” (PNSD #2009/026); the Catalan Government (SGR2009-00131); and the ICREA Foundation (ICREA Academia-2008). KK-T was supported by a Marie Curie Intra-European Fellowship from the European Commission (MC-2010-274950)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dissociation of the pharmacological effects of THC by mTOR blockade

  • Puighermanal Puigvert, Emma, 1983-
  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Marsicano, Giovanni
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
The potential therapeutic benefits of cannabinoid compounds have raised interest in understanding the molecular mechanisms that underlie cannabinoid-mediated effects. We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway. In the present study, we assess the relevance of the mTOR pathway in other acute and chronic pharmacological effects of THC. The rapamycin derivative temsirolimus, an inhibitor of the mTOR pathway approved by the Food and Drug Administration, prevents both the anxiogenic- and the amnesic-like effects produced by acute THC. In contrast, THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception are not sensitive to the mTOR inhibition. In addition, a clear tolerance to THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception was observed after chronic treatment, but not to its anxiogenic- and amnesic-like effects. Temsirolimus pre-treatment prevented the amnesic-like effects of chronic THC without affecting the downregulation of CB1 receptors (CB1R) induced by this chronic treatment. Instead, temsirolimus blockade after chronic THC cessation did not prevent the residual cognitive deficit produced by chronic THC. Using conditional knockout mice lacking CB1R in GABAergic or glutamatergic neurons, we found that GABAergic CB1Rs are mainly downregulated under chronic THC treatment conditions, and CB1-GABA-KO mice did not develop cognitive deficits after chronic THC exposure. Therefore, mTOR inhibition by temsirolimus allows the segregation of the potentially beneficial effects of cannabinoid agonists, such as the anxiolytic and antinociceptive effects, from the negative effects, such as anxiogenic- and amnesic-like responses. Altogether, these results provide new insights for targeting the endocannabinoid system in order to prevent possible side effects., EP and AB-G were recipients of a predoctoral fellowship, Ministerio de Educación y Cultura. This work was supported by grants from the Ministerio de Ciencia e Innovación (#SAF2009-07309 to AO and # SAF2011-29864 to RM), Instituto de Salud Carlos III (RD06/0001/0001 to RM), PLAN E/n(Plan Español para el Estímulo de la Economía y el Empleo), the European Commission/n(PHECOMP #LSHM-CT-2007-037669 to RM), Generalitat de Catalunya (SGR-2009-00731/nto RM), INSERM to GM, European Research Council (ENDOFOOD, ERC-2010-StG-/n260515, to GM), Fondation pour la Recherche Medicale to GM, and ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to RM
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Influence of δ-opioid receptors in the behavioral effects of nicotine

  • Berrendero Díaz, Fernando, 1971-
  • Plaza-Zabala, Ainhoa, 1982-
  • Galeote González, Lola
  • Flores de los Heros, África, 1985-
  • Bura, S. Andreea, 1978-
  • Kieffer, Brigitte L.
  • Maldonado, Rafael, 1961-
Multiple studies in animal models and humans suggest that the endogenous opioid system is an important neurobiological substrate for nicotine addictive properties. In this study, we evaluated the participation of δ-opioid receptors in different behavioral responses of nicotine by using δ-opioid receptor knockout mice. Acute nicotine administration induced hypolocomotion and antinociception in wild-type mice, which were similar in knockout animals. The development of tolerance to nicotine-induced antinociception was also similar in both genotypes. In agreement, the expression and functional activity of δ-opioid receptors were not modified in the different layers of the spinal cord and brain areas evaluated after chronic nicotine treatment. The somatic manifestation of the nicotine withdrawal syndrome precipitated by mecamylamine was also similar in wild-type and δ-opioid receptor knockout mice. In contrast, nicotine induced a conditioned place preference in wild-type animals that was abolished in knockout mice. Moreover, a lower percentage of acquisition of intravenous nicotine self-administration was observed in mice lacking δ-opioid receptors as well as in wild-type mice treated with the selective δ-opioid receptor antagonist naltrindole. Accordingly, in-vivo microdialysis studies revealed that the enhancement in dopamine extracellular levels induced by nicotine in the nucleus accumbens was reduced in mutant mice. In summary, the present results show that δ-opioid receptors are involved in the modulation of nicotine rewarding effects. However, this opioid receptor does not participate either in several acute effects of nicotine or in the development of tolerance and physical dependence induced by chronic nicotine administration., This work was supported by the Spanish “Ministerio de Ciencia e Innovación”/n(#SAF2007-64062 and #SAF-2011-29864), the “Instituto de Salud Carlos III” grants/n#PI07/0559, #PI10/00316 and #RD06/001/001, the “Plan Nacional Sobre Drogas”/n(#2009/026), the Catalan Government (SGR2009-00131), and the ICREA Foundation/n(ICREA Academia Award-2008) to R.M. Partial support of FEDER funds is also acknowledged.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids

  • Puighermanal Puigvert, Emma, 1983-
  • Busquets Garcia, Arnau, 1985-
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Exogenous cannabinoids, such as delta9-tetrahydrocannabinol (THC), as well as the modulation of endogenous cannabinoids, affect cognitive function through the activation of cannabinoid receptors. Indeed, these compounds modulate a number of signalling pathways critically implicated in the deleterious effect of cannabinoids on learning and memory. Thus, the involvement of the mammalian target of rapamycin pathway and extracellular signal-regulated kinases, together with their consequent regulation of cellular processes such as protein translation, play a critical role in the amnesic-like effects of cannabinoids. In this study, we summarize the cellular and molecular mechanisms reported in the modulation of cognitive function by the endocannabinoid system., EP is a recipient of an EMBO Fellowship with the support of European Commission (EMBOCOFUND2010, GA-2010-267146) and Marie Curie Actions. AB-G is a recipient of a predoctoral fellowship, Spanish Ministry of Education and Culture. This study was supported by grants from La Marató de TV3 (#090910 to AO), Grants from the Spanish Ministry of Science and Innovation (#SAF2009-07309 to AO and/n#SAF2011-29864 to RM); Instituto de Salud Carlos III (RD06/0001/0001 to RM); PLAN E (Plan Español para el Estímulo de la Economía y el Empleo); Generalitat de Catalunya (SGR-2009-00731 to RM and SGR-2009-00718 to RdlT); ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to RM
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations

  • Varani, Andrés P.
  • Aso Pérez, Ester
  • Machado Moutinho, Lirane
  • Maldonado, Rafael, 1961-
  • Balerio, Graciela N.
RATIONALE: Nicotine is a major active ingredient in tobacco and plays a major role in tobacco addiction. In rodents, repeated nicotine administration produces behavioral responses related to its addictive properties, such as reinforcing effects and physical dependence. OBJECTIVES: The aim of the present study was to evaluate the possible role of GABAB receptor in responses induced by repeated nicotine administration in Swiss Webster mice. RESULTS: Nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.) administration induced rewarding properties in the conditioning place preference test. The GABAB receptor agonist, baclofen (3 mg/kg, i.p.) abolished the rewarding properties induced by nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.). In addition, naloxone-precipitated nicotine withdrawal induced somatic manifestations, anxiety-like effects in the elevated plus maze test and dysphoric manifestations in the conditioned place aversion paradigm. Baclofen (2 and 3 mg/kg, i.p.) prevented the somatic manifestations and the anxiety-like effects associated with naloxone-precipitated nicotine withdrawal but not the dysphoric manifestations. CONCLUSIONS: These results showed that nicotine rewarding properties and negative aspects of nicotine withdrawal, such as anxiety-like effects and somatic manifestations, can be modulated by the GABAB receptor activity. This study now reveals a novel possible application of baclofen to develop new therapeutic strategies to achieve smoking cessation., This work has been supported by grants from University of Buenos Aires (UBACyT B016 and UBACyT 2013-2016 Nº 20020120100244), CONICET (PIP 11420090100303), Spanish “Ministerio de Ciencia e Innovación” (#SAF2011-29864), “Instituto de Salud Carlos III” (RETICS: #RD06/0001/0001, #RD06/0001/1004), Plan Nacional sobre Drogas (PNSD#2009/026), the CatalanGovernment/n(SGR2009-00131), and the ICREA Foundation (ICREA Academia-2008). Andrés P. Varani is a doctoral fellow of the University of Buenos Aires (677/10).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Morphine-induced locomotor sensitization produces structural plasticity in the mesocorticolimbic system dependent on CB1-R activity

  • Guegan, Thomas, 1983-
  • Cebrià i Costa, Joan Pau, 1989-
  • Maldonado, Rafael, 1961-
  • Martín Sánchez, Miquel, 1971-
Changes in structural plasticity produced by the chronic exposure to drugs of abuse, such as alterations in dendritic spine densities, participate in the development of maladaptive learning processes leading to drug addiction. Understanding the neurobiological mechanisms involved in these aberrant changes is crucial to clarify the neurobiological substrate of addiction. Drug-induced locomotor sensitization has been widely accepted as a useful animal model to study these mechanisms related to drug addiction. We have evaluated the changes in structural plasticity in the mesocorticolimbic system involved in morphine-induced locomotor sensitization. The role of the cannabinoid receptor type 1 (CB1-R) in these neuroplastic alterations has also been studied using CB1-R-deficient (CB1-R KO) mice. Structural plasticity changes promoted by morphine are a highly dynamic phenomenon that evolves during the entire time course of the behavioral sensitization in wild-type (WT) animals. The different phases of the sensitization process were related to specific changes in connectivity between neurons revealed by modifications in dendritic spines in specific areas of the mesocorticolimbic system. Moreover, the lack of morphine-induced locomotor sensitization in CB1-R KO mice was accompanied by abnormal alterations in structural plasticity in the same mesocorticolimbic areas. These specific structural plasticity changes mediated by CB1-R activity seem necessary for the normal progression of morphine-induced locomotor sensitization and could play a critical role in the addictive process., This work was supported by European Commission-FP7 (#HEALTH-F2-2013-602891), RETICS-Instituto de Salud Carlos III (#RD12/0028/0023), MICINN-Ministerio de Ciencia e Innovación (#SAF2011-29864) and AGAUR-Generalitat de Catalunya (#2009SGR00731 and #2014-SGR-1547). FEDER co-funding is also acknowledged
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward

  • Flores de los Heros, África, 1985-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
BACKGROUND: Cannabis is the most widely used illicit drug in the world. Although there is a high prevalence of users who seek treatment for cannabis dependence, no accepted pharmacologic treatment is available to facilitate and maintain abstinence. The hypocretin/orexin system plays a critical role in drug addiction, but the potential participation of this system in the addictive properties of cannabinoids is unknown. METHODS: We investigated the effects of hypocretins in the intravenous self-administration of the synthetic cannabinoid agonist WIN55,212-2 using hypocretin receptor-1 (Hcrtr-1) and hypocretin receptor-2 antagonists and Hcrtr-1 knockout mice. Additional groups of mice were trained to obtain water to rule out operant responding impairments. Activation of hypocretin neurons was analyzed by using double-label immunofluorescence of FosB/ΔFosB with hypocretin-1. Microdialysis studies were performed to evaluate dopamine extracellular levels in the nucleus accumbens after acute Δ(9)-tetrahydrocannabinol administration.RESULTS: Systemic administration of the Hcrtr-1 antagonist SB334867 reduced intravenous self-administration of WIN55,212-2, as well as the maximum effort to obtain a WIN55,212-2 infusion, as revealed under a progressive ratio schedule. This role of Hcrtr-1 in the reinforcing and motivational properties of WIN55,212-2 was confirmed in Hcrtr-1 knockout mice. Contingent, but not noncontingent, WIN55,212-2 self-administration increased the percentage of hypocretin cells expressing FosB/ΔFosB in the lateral hypothalamus. The enhancement in dopamine extracellular levels in the nucleus accumbens induced by Δ(9)-tetrahydrocannabinol was blocked in mice lacking the Hcrtr-1. CONCLUSIONS: /nThese findings demonstrate that Hcrtr-1 modulates the reinforcing properties of cannabinoids, which could have a clear therapeutic interest., This work was supported by the Instituto de Salud Carlos III grants, #PI07/0559, #PI10/00316 and #RD06/001/001 (RTA-RETICS), by the Spanish Ministry of Science and Technology, Consolider-C #SAF2007-64062 and #SAF2011-29864, the Catalan Government (SGR2009-00731), and by the Catalan Institution for Research and Advanced Studies (ICREA Academia program). África Flores is recipient of a predoctoral fellowship from the Spanish Ministry of Education
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Differential regulation of mGlu5 R and ΜOPr by priming- and cue-induced reinstatement of cocaine-seeking behaviour in mice

  • Georgiou, Polymnia
  • Zanos, Panos
  • Ehteramyan, Mazdak
  • Hourani, Susanna
  • Kitchen, Ian
  • Maldonado, Rafael, 1961-
  • Bailey, Alexis
The key problem for the treatment of drug addiction is relapse to drug use after abstinence that can be triggered by drug-associated cues, re-exposure to the drug itself and stress. Understanding the neurobiological mechanisms underlying relapse is essential in order to develop effective pharmacotherapies for its prevention. Given the evidence implicating the metabotropic glutamate receptor 5 (mGlu5 R), μ-opioid receptor (MOPr), κ-opioid receptor (ΚOPr) and oxytocin receptor (OTR) systems in cocaine addiction and relapse, our aim was to assess the modulation of these receptors using a mouse model of cue- and priming-induced reinstatement of cocaine seeking. Male mice were trained to self-administer cocaine (1 mg/kg/infusion, i.v.) and were randomized into different groups: (1) cocaine self-administration; (2) cocaine extinction; (3) cocaine-primed (10 mg/kg i.p.); or (4) cue-induced reinstatement of cocaine seeking. Mice undergoing the same protocols but receiving saline instead of cocaine were used as controls. Quantitative autoradiography of mGlu5 R, MOPr, KOPr and OTR showed a persistent cocaine-induced upregulation of the mGlu5 R and OTR in the lateral septum and central amygdala, respectively. Moreover, a downregulation of mGlu5 R and MOPr was observed in the basolateral amygdala and striatum, respectively. Further, we showed that priming- but not cue-induced reinstatement upregulates mGlu5 R and MOPr binding in the nucleus accumbens core and basolateral amygdala, respectively, while cue- but not priming-induced reinstatement downregulates MOPr binding in caudate putamen and nucleus accumbens core. This is the first study to provide direct evidence of reinstatement-induced receptor alterations that are likely to contribute to the neurobiological mechanisms underpinning relapse to cocaine seeking., This work was supported by Spanish‘ Ministerio de Ciencia e Innovación’ (SAF 2011–29864) and Lilia and Charalambos Georgiou
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far

  • Flores de los Heros, África, 1985-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
Emerging findings suggest the existence of a cross-talk between hypocretinergic and endocannabinoid systems. Although few studies have examined this relationship, the apparent overlap observed in the neuroanatomical distribution of both systems as well as their putative functions strongly point to the existence of such cross-modulation. In agreement, biochemical and functional studies have revealed the existence of heterodimers between CB1 cannabinoid receptor and hypocretin receptor-1, which modulates the cellular localization and downstream signaling of both receptors. Moreover, the activation of hypocretin receptor-1 stimulates the synthesis of 2-arachidonoyl glycerol culminating in the retrograde inhibition of neighboring cells and suggesting that endocannabinoids could contribute to some hypocretin effects. Pharmacological data indicate that endocannabinoids and hypocretins might have common physiological functions in the regulation of appetite, reward and analgesia. In contrast, these neuromodulatory systems seem to play antagonistic roles in the regulation of sleep/wake cycle and anxiety-like responses. The present review attempts to piece together what is known about this interesting interaction and describes its potential therapeutic implications., This work was supported by the Instituto de Salud CarlosIII grants, #PI07/0559, #PI10/00316 and #RD06/001/001 (RTA-RETICS), by the Spanish Ministry of Science and Technology, Consolider-C #SAF2007-64062 and #SAF2011-29864, the Catalan Government (SGR2009-00731), and by the Catalan Institution for Research and Advanced Studies (ICREA Academia program). África Flores is recipient of a predoctoral fellowship from the Spanish Ministry of Education
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB and Serotonin 5-HT Receptors

  • Viñals, Xavier
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Lanfumey, Laurence
  • Cordomí Montoya, Arnau|||0000-0002-3848-2928
  • Pastor, Antoni|||0000-0003-3692-0696
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Gasperini, Paola
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Howell, Lesley A.
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Lluís, Carme
  • Canela, Enric I.|||0000-0003-4992-7440
  • McCormick, Peter J.
  • Maldonado, Rafael|||0000-0002-4359-8773
  • Robledo, Patricia
Activation of cannabinoid CB1 receptors (CBR) by delta9-tetrahydrocannabinol (THC) produces a variety of negative effects with major consequences in cannabis users that constitute important drawbacks for the use of cannabinoids as therapeutic agents. For this reason, there is a tremendous medical interest in harnessing the beneficial effects of THC. Behavioral studies carried out in mice lacking 5-HT receptors (5-HTR) revealed a remarkable 5-HTR-dependent dissociation in the beneficial antinociceptive effects of THC and its detrimental amnesic properties. We found that specific effects of THC such as memory deficits, anxiolytic-like effects, and social interaction are under the control of 5-HTR, but its acute hypolocomotor, hypothermic, anxiogenic, and antinociceptive effects are not. In biochemical studies, we show that CBR and 5-HTR form heteromers that are expressed and functionally active in specific brain regions involved in memory impairment. Remarkably, our functional data shows that costimulation of both receptors by agonists reduces cell signaling, antagonist binding to one receptor blocks signaling of the interacting receptor, and heteromer formation leads to a switch in G-protein coupling for 5-HTR from Gq to Gi proteins. Synthetic peptides with the sequence of transmembrane helices 5 and 6 of CBR, fused to a cell-penetrating peptide, were able to disrupt receptor heteromerization in vivo, leading to a selective abrogation of memory impairments caused by exposure to THC. These data reveal a novel molecular mechanism for the functional interaction between CBR and 5-HTR mediating cognitive impairment. CBR-5-HTR heteromers are thus good targets to dissociate the cognitive deficits induced by THC from its beneficial antinociceptive properties. Specific subtypes of cannabinoid and serotonin receptors interact to form heterodimers that mediate the cognitive deficits-but not the analgesic effects-induced by tetrahydrocannabinol, the major psychoactive constituent in Cannabis sativa. Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound of marijuana, induces numerous undesirable effects, including memory impairments, anxiety, and dependence. Conversely, THC also has potentially therapeutic effects, including analgesia, muscle relaxation, and neuroprotection. However, the mechanisms that dissociate these responses are still not known. Using mice lacking the serotonin receptor 5-HT, we revealed that the analgesic and amnesic effects of THC are independent of each other: while amnesia induced by THC disappears in the mutant mice, THC can still promote analgesia in these animals. In subsequent molecular studies, we showed that in specific brain regions involved in memory formation, the receptors for THC and the 5-HT receptors work together by physically interacting with each other. Experimentally interfering with this interaction prevented the memory deficits induced by THC, but not its analgesic properties. Our results highlight a novel mechanism by which the beneficial analgesic properties of THC can be dissociated from its cognitive side effects.